Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 1 2021.01.30  NCT#:   [STUDY_ID_REMOVED]  
Whitecap  Biosciences – CONFIDENTIAL  
This pr otocol contains confidential  information  intended solely  for the recipient  clinical  
investigator(s), IRBs/IECs,  and regulatory agencies.   This protocol and  all related  study 
materials  are the property of Whitecap  Biosciences  and must not be copied by or distributed  
by persons not involved in  this clinical  investigation without prior written  consent from  
Whitecap  Biosciences.  
STUDY  TITLE  
A Phase 1/2a Assessment  of WB007 Ophthalmic  Solution in Subjects  with  Primary  Open -
Angle Glaucoma or  Ocular  Hypertension 
Protocol  Number:    WB007-001 
EudraCT  Number:  Not Applicable  
Phase:  1/2 
Investigational  Product:  WB007  (also  known  as AGN -227535 ) 
Sponsor:  Whitecap  Biosciences  
6789 Quail  Hill Pkwy  Suite  719 
Irvine,  CA 92603  
Medical  Safety  Physician   
Contact  information: Robert  David,  MD 
robert.david@clindevop.com  
Tel:  +1.949.200.7988  
Emergency  Telephone  Number:  
(Dr. David)  1-949-246-8368  
SAE Reporting:  wb007 @JANIX.co m 
Whitecap  Biosciences,  LLC Signatory:  Scott  M Whitcup,  MD 
Chief  Executive  Officer  
 
 _
____________________________   ____________  
Scott  M Whitcup,  MD   Date  
 
 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 2 2021.01.30  INVESTIGATOR SIGNATURE  PAGE  
INVESTIGATOR:  
  
STUDY LOCATION:   
 
I agree to: 
• Implement and  conduct this study diligently  and in strict compliance with  the protocol, 
Good Clinical Practices  and all  applicable laws  and regulations. 
• Maintain  all information  supplied by Whitecap  Biosciences  in confidence and, when  this 
information  is submitted  to an Institutional Review  Board  (IRB),  Independent Ethics  
Committee  (IEC) or another group, it will be submitted  with  a designation that  the 
material  is confidential. 
I have read  this protocol in its entirety  and I agree to all aspects.  
     
Investigator Printed  Name  Signature  Date  
 
RETURN TO WHITECAP BIOSCIENCES WITH ATTACHED PROTOCOL 
 
         
 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 3 2021.01.30  Table  of Contents  
Protocol Synopsis ................................................................................................................................... 7  
1. Background and  Rationale  ...................................................................................................... 14  
1.1. Background ............................................................................................................................. 14  
1.2. Investigational Product ............................................................................................................ 14  
1.3. Summary  of Nonclinical  Studies ............................................................................................. 14  
1.4. Benefit/Risk  Assessment  ......................................................................................................... 16  
2. Study Purpose, Objectives,  and Clin ical Hypothesis(es) ........................................................ 16  
3. Study Design  and Rationale  .................................................................................................... 16  
3.1. Study Endpoints ...................................................................................................................... 18  
3.1.1.  Primary  Efficacy  Endpoint(s) .................................................................................................. 18  
3.1.2.  Secondary Efficacy  Endpoint(s) .............................................................................................. 18  
3.2. Methods for Randomization, Stratification,  Masking, and Minimization  of Bias  .................. 18  
3.2.1.  Randomization and  Stratification  (Part  2 Only)  ...................................................................... 18  
3.2.2.  Masking  ................................................................................................................................... 18  
3.2.3.  Minimization  of Bias ............................................................................................................... 19  
3.3. Treatment  Stopping Rules  and Discontinuation  Criteria  ......................................................... 19  
3.3.1.  Treatment  Stopping Rules  ....................................................................................................... 19  
3.3.2.  Discontinuation Criteria  .......................................................................................................... 19  
3.4. Decision  Making  During  Parts  1 and  2 ................................................................................... 20  
4. Study Population ..................................................................................................................... 20  
4.1. Inclusion Criteria  ..................................................................................................................... 20  
4.2. Exclusion Criteria  .................................................................................................................... 22  
4.3. Lifestyle  Considerations .......................................................................................................... 24  
4.4. Screen  Failures  ........................................................................................................................ 25  
4.5. Rationale for  Inclusion and  Exclusion Criteria  ....................................................................... 25  
5. Study Treatments  ..................................................................................................................... 25  
5.1. Investigational Product ............................................................................................................ 25  
5.1.1.  Preparation/Handling/Storage/Accountability ........................................................................ 26  
5.2. Study Treatment  Administration  ............................................................................................. 27  
5.2.1.  Study Treatment  Regimen  and Dosing .................................................................................... 27  
5.2.2.  Treatment  Compliance  ............................................................................................................ 28  
6. Concomitant Treatments and Medications  .............................................................................. 28  
6.1. Prohibited Treatments  and Medications  .................................................................................. 28  
6.2. Washout/Waiting  Period  ......................................................................................................... 29  
6.2.1.  Washout  Period  ....................................................................................................................... 29  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 4 2021.01.30  6.2.2.  Considerations During  Washout Period  .................................................................................. 30  
6.2.3.  Waiting  Period  ......................................................................................................................... 30  
6.3. Permissible  Medications and Treatments  ................................................................................ 30  
6.4. Pregnancy and  Contraception  Considerations ......................................................................... 31  
6.4.1.  Pregnancy Considerations ....................................................................................................... 31  
6.4.2.  Acceptable Contraception  ....................................................................................................... 31  
6.4.3.  Procedures for  Pregnancy Follow-up and  Reporting .............................................................. 31  
7. Study Assessments  .................................................................................................................. 32  
7.1. Demographics and Baseline  Characteristics  ........................................................................... 32  
7.2. Efficacy  Assessments  .............................................................................................................. 32  
7.3. Safety  Assessments  ................................................................................................................. 32  
7.4. Other  Assessments  .................................................................................................................. 33  
7.5. Methods of  Data  Collection  .................................................................................................... 33  
8. Study Conduct ......................................................................................................................... 34  
8.1. Informed Consent .................................................................................................................... 35  
8.2. Subject Screening  Visit /Screening  Period  (Days  –50 to –4) .................................................. 35  
8.3. Subject Enrollment  – Baseline Visit  (Day  -1) ......................................................................... 37  
8.3.1.  Procedures Prior to  Randomization (Part  2 only) .................................................................... 38  
8.3.2.  Randomization Procedures (Part  2 only)  ................................................................................. 38  
8.4. Study Visits  and Procedures for  Enrolled  Subjects  ................................................................. 38  
8.4.1.  Part 1 - Study Visits  and Procedures for Enrolled  Subjects  .................................................... 38  
8.4.2.  Part 2 - Study Visits  and Procedures for Enrolled  Subjects  .................................................... 40  
8.5. Unscheduled  Visits  and Associated  Procedures  ...................................................................... 42  
8.6. Instructions for Subjects  .......................................................................................................... 42  
8.7. Safety  Monitoring.................................................................................................................... 44  
8.7.1.  Procedures for  Collecting  and Reporting Adverse Events  ...................................................... 44  
8.7.2.  Severity  .................................................................................................................................... 45  
8.7.3.  Relationship  to Study Drug  or Study Procedure ..................................................................... 45  
8.7.4.  Procedures for  Reporting a Serious  Adverse  Event  ................................................................ 45  
8.8. Procedures for  Stopping Study Treatment  .............................................................................. 46  
8.9. Early  Study  Exit  Procedures .................................................................................................... 46  
8.9.1.  Subject Discontinuation/Withdrawal from  the Study .............................................................. 46  
8.9.2.  Lost to Follow  Up.................................................................................................................... 47  
8.10. Procedures for  Unmasking  of Study  Medication  .................................................................... 48  
9. Statistical  Procedures .............................................................................................................. 48  
9.1. Analysis Population(s) ............................................................................................................ 48  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 5 2021.01.30  9.2. Sample  Size  Calculation  .......................................................................................................... 49  
9.3. Methods of  Analyses ............................................................................................................... 50  
9.3.2.  Safety  Analyses ....................................................................................................................... 51  
9.4. Other  Analyses  ........................................................................................................................ 52  
9.5. Subgroup Analyses  .................................................................................................................. 52  
9.6. Interim  Analyses ...................................................................................................................... 52  
10. Supporting Documentation  and Operational Considerations .................................................. 52  
10.1. Regulatory, Ethical,  and Study Oversight Considerations  ...................................................... 52  
10.1.1.  Regulatory and Ethical Considerations ................................................................................... 52  
10.1.2.  Financial  Disclosure  ................................................................................................................ 53  
10.1.3.  Informed Consent Process  ....................................................................................................... 53  
10.1.4.  Data  Protection  ........................................................................................................................ 54  
10.1.5.  Coordinating Investigator ........................................................................................................ 54  
10.2. Protection of  Human  Subjects  ................................................................................................. 54  
10.2.1.  Subject Confidentiality  ............................................................................................................ 54  
10.2.2.  Subject Privacy  ........................................................................................................................ 54  
10.2.3.  Compliance with  Informed  Consent Regulations  and Relevant  Country Regulations  ............ 55  
10.2.4.  Compliance with  IRB  Regulations  .......................................................................................... 56  
10.2.5.  Compliance with  Good Clinical Practice ................................................................................ 56  
10.3. Changes to the Protocol ........................................................................................................... 56  
10.4. Documentation ........................................................................................................................ 56  
10.4.1.  Source Documents  ................................................................................................................... 56  
10.4.2.  Compliance with  Electronic Records;  Electronic  Signatures Regulations  .............................. 58  
10.4.3.  Case Report  Form  Completion  ................................................................................................ 58  
10.4.4.  Data  Quality  Assurance  ........................................................................................................... 58  
10.4.5.  Study and  Site Closure  ............................................................................................................ 59  
10.4.6.  Final  Report  by Investigator  .................................................................................................... 59  
10.4.7.  Retention  of Documentation  ................................................................................................... 59  
10.5. Monitoring by Whitecap  Biosciences  ..................................................................................... 60  
10.6. Publications ............................................................................................................................. 60  
11. References  ............................................................................................................................... 61  
12. Attachments  ............................................................................................................................. 62  
12.1. Glossary  of Terms,  Abbreviations and Definitions  ................................................................. 62  
12.2. Examination  Procedures,  Tests,  Equipment, and Techniques ................................................. 65  
12.2.1.  Demographics and Baseline  Characteristics  ........................................................................... 65  
12.2.2.  Ophthalmic Examination  Procedures,  Tests,  Equipment, and Techniques  ............................. 67  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 6 2021.01.30  12.3. Other  Study Supplies ............................................................................................................... 74  
12.4. List of Computerized  Systems ................................................................................................ 74  
12.5. Protocol Amendments  ............................................................................................................. 75  
12.5.1.  Amendment  1 Summary .......................................................................................................... 75  
12.5.2.  Amendment  2 Summary .......................................................................................................... 77  
12.5.3.  Amendment  3 Summary .......................................................................................................... 78  
12.5.4.  Amendment  4 Summary .......................................................................................................... 78  
12.5.5.  Amendment  5 Summary .......................................................................................................... 79  
  
List of Tables  
Table  1 Scheduled  Visits  and Procedures - Screening  and Baseline  (Parts  1 and 2) ....................... 11 
Table  2 Part 1 - Schedule of  Visits  and Procedures:   Days  1 and  2................................................. 12 
Table  3 Part 2 - Schedule of  Visits  and Procedures:   Day  1 to Day 14/Exit ................................... 13 
Table  4 Formulation Characteristics for AGN-227535/WB007  (Study  Treatments 1- 3) .............. 26 
Table  5 Minimum Washout Period  ................................................................................................. 29 
Table  6 Power  Calculations  for Study  Part 2 Tests  of Treatment  Differences ................................ 49 
Table  7 Glossary  of Terms  and Abbreviations ................................................................................ 62 
Table  8 G lossary  of Definitions ....................................................................................................... 64 
 
List of Figures 
Figure 1  Schematic of  Study Design  ................................................................................................ 10 
Figure 2  Part 1 Dose  Escalation   ....................................................................................................... 10 
Figure 3  Part 2 Parallel  Comparison ................................................................................................. 10 
 
  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 7 2021.01.30  Protocol  Synopsis  
Study  Title :  A Phase 1/2a Assessment  of WB007  Ophthalmic  Solution in  Subjects  with  
Primary  Open -Angle Glaucoma or Ocular  Hypertension 
Investigational Product :  WB007 (also  known as  AGN-227535)  
Phase:   1/2a 
Study  Objectives:   The  objective of this  study is  to assess the safety,  ocular  tolerability  and 
IOP-lowering effects  of AGN-227535 in  adult subjects  with  bilateral  primary  open-angle 
glaucoma or ocular  hypertension. 
Clinical Hypotheses:    
Parts  1/2:  AGN-227535 has  an acce ptable safety  and tolerability  profile;  
Part 1: The safety  profile  allows  for assessing  AGN-227535 in  Part 2; 
Part 2:   At least  1 concentration  of AGN-227535 demonstrate s an IOP lowering effect . 
Type  of Study:   Two-part, multi- centered  [(Part  1- single-dose  in one eye, open -labeled,  
dose- escalation),  (Part  2 - multiple -dose, randomized, double- masked,  active -controlled)], 
bilateral  treatment.   
Study  Population:  Adult (at  least  18 years  of age)  male  or female subjects  with primary  
open-angle glaucoma or ocular  hypertension in  each  eye who  are otherwise  in generally  good 
health .  Only  one eye must meet  all ocular  entry  criteria.    
Number  of Subjects  and Sites : Approximately 100 subjects  will be screened  to participate  
in the study (Part  1 – 25; Part  2 – 75).  An expected  95 subjects  will be assigned  to study 
treatment  such  that approximately  18 (Part  1) and  60 (Part  2) subjects  complete  the study at  
3-5 sites.   Subjects  who  do not complete  the study may  be replaced.    
Part 1: Approximately 6 subjects  per dose- escalation  cohort (up  to 3). 
Part 2:  Up to 2 investigational doses will be chosen  based  on results  from  Part 1.  
Approximately 24 subjects per  AGN-227535 group and  approximately 12 subjects  
for the timolol group will be given study treatment.    
Duration of Study  Participation:    
Part 1: Up to 2 months from  Screening  through Day  2/Exit;   
Part 2: Up to 2.5 months from  Screening  through Day 14/Exit.  
Study  Treatments :  AGN-227535 Ophthalmic  Solution (Parts  1 and  2) and  timolol 0.5% 
ophthalmic solution (as  a control in  Part 2 only) 
Part 1: Study Treatment s 1-3:   AGN-227535 (0.05%; 0.15%; 0.40%);    
Part 2: Up to 2 AGN-227535 study treatments  and Timolol 0.5% (Study Treatment  4). 
Dosage/Dose Regimen:    
Part 1: Subjects  will be given 1 dose of study treatment  to one eye in  the morning 
(administered  by site  personnel). 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 8 2021.01.30  Part 2: Subjects  will dose study treatment  every  morning and every  evening 
(approximately 12 hours apart)  to each  eye for up to 14 days.  Site  personnel will 
administer  the morning dose at  study visits.  
Randomization/Stratification: 
Part 1: If only one eye qualifies,  the study medication  will be administered  to that eye.   If 
both eyes  qualify, the eye with  the higher IOP at Baseline (Day  -1) Hour 0 will be 
the study eye an d will receive study medication.   If both eyes  have the same IOP 
value at  this timepoint,  the right eye will be the study eye.  
Part 2: Part 2:  Subjects  will be randomly assigned  to 1 of up to  3 treatment  arms  (based  
on results  from  Part 1) in  a 2(:2):1  allocation  ratio  to receive 1 of  up to  2 AGN-
227535 concentrations or timolol 0.5% in  each  eye.  The  randomization will be 
stratified  by baseline IOP (IOP ≤ 25 mm Hg  and > 25 mm Hg  at Hour 0) and  
performed  centrally  (ie, across  sites).   Randomization and  stratification  will be 
performed  using the Interactive Web  Response System  (IWRS), a module within  
the electronic data capture (eDC)  system . 
Visit  Schedule:   
Part 1: Screening  (days  -50 to  -4, including washout/waiting  period as  required ); Baseline 
(Day  -1), Day  1, Day  2/Exit 
Part 2: Screening  (days  -50 to  -4, including washout/waiting  period as  required; Baseline  
(Day  -1), Day  1, Day  4 and Day  14/Exit. 
Primary  Efficacy  Endpoint  (Part  2 only):   Mean  change from  baseline in  IOP 
Statistical  Method  for primary  endpoint:    
In general,  data will be summarized  with  descriptive statistics  which  will include sample  
size, mean,  standard  deviation, median,  minimum and maximum for continuous variables  
and frequency  and percentage for categorical  variables.  
The Medical  Dictionary  for Regulatory Activities  (MedDRA)  nomenclature will be used  to 
code adverse events.  The number and  percentage of subjects  with  adverse event  reports  will 
be tabulated  for all  treatment -emergent  adverse events (T EAEs ) regardless  of causality,  
treatment -related  TEAEs,  all serious TEAEs,  treatment -related  serious TEAEs,  and all 
adverse events  leading  to premature discontinuation of study treatment.   
Analy sis populations: Each  population will be analyzed  based  on the treatment  received.  
Part 1:  The Safety  population consisting  of all  treated  subjects  will be used  for all 
analyses.   All safety  and IOP-lowering effects  tabulations  will provide descriptive 
statistics  by cohort. 
Part 2: The Safety  population, as  defined  above,  will be used  for analyses  of all  Safety  
data.  In addition to  the Safety  population two  other populations are defined  for 
analyses  of Part  2 efficacy  data:  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 9 2021.01.30  The Modified Intent- to-treat (mITT)  will consist of all  randomized  and treated  subjects  who  
provide IOP  data at baseline and  at least  one post- baseline IOP  assessment.   This population 
will be used  for analyses  of efficacy  data.  
The Per-protocol (PP)  population is  a subset of the mITT  population and  will consist of 
subjects  who  did not have any  major  protocol violations deemed  to have potential impact  on 
the primary  endpoint.  This population will be used  to confirm  the primary  efficacy  analysis.  
The primary  efficacy  endpoints are the Da y 14/Exit  mean  IOP changes from  Baseline (Day  -
1) at each  time -matched  hour (0,  2, 4, 8) in  the study eye.  The primary  efficacy  analysis  will 
be within -group mean  change from  baseline IOP  at hour 2, the time  of peak  effect  of timolol.  
Between  treatment group comparative analyses  will be performed  in the mITT  population via 
analysis  of co variance (AN COV A)  tests  which  will have treatment  as the main  effect  and the 
baseline hour- matched  IOP as the covariate in  the model.  Pairwise  treatment group 
comparisons will be performed  for each  individual dose of AGN-227535 ophthalmic  solution 
versus timolol ophthalmic solution 0.5%.  Confidence intervals  (95%) based  on this  
ANC O VA  model will be provided for the differences  between  treatment  groups.  AGN-
227535 will be considered to  be non- inferior to  Timolol 0.5% if  the upper limit of the 95% 
CI does not exceed  1.5 mm Hg  at the majority  of timepoints  evaluated  (ie, 3/4) at  the Day  
14/Exit visit.   If AGN-227535 ophthalmic solution is  determined  to be non- inferior to  
Timolol ophthalmic solution 0.5%, a further attempt  to show superiority of AGN-227535 
over Timolol will be made.   These analyses  will also  be performed  on the PP  population.  As 
this is an exploratory trial,  all treatment  comparisons will be made at  the two -sided  α = 0.05 
level  without adjustment for multiple  comparisons. 
Additional safety  analyses  will include evaluation  of peak  severity  of macroscopic hyperemia 
and hyperemia as evaluated  on biomicroscopy at  each  post- basel ine visit (Days  4 and  14) and  
across  all post- baseline time  points. 
Sample  Size Calculation:  For each  cohort in  Part 1 of the study a sample  size of 6 patients  
will provide 83% power to  detect  a 3 mm Hg  within -group change from  pre-dose assuming a 
standard  deviation of 2 and two -sided  alpha = 0.05.  
Part 2 sample  size will provide >90 % power to  detect  within -group and  between -group 
treatment  differences  of mean  change from  baseline of at  least  3 mm Hg  for the primary  
endpoint ass uming a standard  deviation of 2.5 with  two-sided  alpha = 0.05.  With  a treatment  
group difference  of -1 mmHg,  the power ranged  from  50% for a common SD  of 3.5 to  78% 
for a common SD  of 2.5 to conclude non- inferiority  based  on a 1.5 mmHg  margin  and a 1-
sided alpha = 0.025. 
Data Monitoring Committee:  No  formal  Data Monitoring Committee  is planned.  Between  
dose- escalation  groups in  Part 1, all  available data collected  to date will be used  to assist  in 
decision  making to  continue to  the next dose or to  stop the study.  All data collected  in Part 1 
will be used  to select  1 or 2 concentrations of AGN-227535 to  evaluate in  Part 2.  The 
decision  to proceed  or to  stop the study will be made by the Medical  Monitor, the Head  of 
Clinical and  the Chief  Executive Office r.  All decisions  will be documented. 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 10 2021.01.30  Figure  1  Schematic of Study  Design   
 
Figure  2  Part  1 Dose  Escalation  
Visit  Flow  
 
Dose  Escalation 
 
Figure  3  Part  2 (Parallel  Comparison) 
Visit  Flow   

Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 11 2021.01.30  Table  1 Scheduled Visits  and Procedures  - Screening  and Baseline  (Parts  1 and 2) 
Assessment  Visits  (Visit  Window  ± Day)  Screening  
Days  -50 to -4 
Washout  / Waiting  Period  (-50 to -4 Days) a Baseline  
(Day  -1) 
Timepoint:   All examinations  for all visits  and timepoints  should  be performed  in 
the order  listed  below  from top to bottom ( refer to Attachment  12.2 f or details  on 
how to perform procedures ) Hour  Hour  
Not Applicable  0 2 4 8 
Informed  Consent/Authorization  X     
Adverse  Event  Query  X X    
(Part  2 only)  Subject  Comfort  of Eye Drops  Evaluation  (for subjects  on IOP 
lowering medications;  evaluation to be administered by designated site 
personnel)  X     
Concomitant  Medications/ Treatments  X X    
Medical  and Ophthalmic  Histories  X X    
Prior  Medications/ Treatments  X X    
Physical  Exam  including  height  and weight  X     
Respiration  rate and temperature  (seated ) X X    
Postural  (supine/standing)  Blood  Pressure  & Heart  Rate  X Xb    
Non-fasting  Laboratory  assessments  (CBC  with differential,  Blood  Chemistries,  
Urinalysis)  X     
Electrocardiogram   X    
Urine  Pregnancy  Test (for females  of childbearing  potential)   X    
Macroscopic  (Gross)  Hyperemia  X X X X X 
Pupil  Size (Part  2 only)   X X   
Visual  Acuity (using  Manifest  Refraction)  X X    
Contrast  Sensitivity  (Part  2 only)   X    
Slit-Lamp  Biomicroscopic  Examination  X X X X X 
Intraocular  Pressure  (IOP)c X X X X X 
Visual  Fieldsd X X 
Fundus  Exam  (including  cup/disc  ratio) (post -pupil  dilation)  X     
NOTE :  CBC - Complete  blood count; H = hour  (hour  0 = 07:00 to  09:00 hours )  
a Washout  / Waiting Period (Day  -50 to Day -4).  For subjects  taking IOP-lowering medications,  the washout  must  be completed 
according to the schedule in Section 6.2.  For subjects  who are not taking IOP-lowering medications,  a 3-day waiting period from 
Screening to  Baseline is  required.   
b At Baseline,  blood pressure and heart  rate will be measured in the supine position only.  
c IOP should be measured before pupil  dilation (as  applicable)   
d Results  of 2 reliable visual  field (VF) examinations  are required for  eligibility.   See Section 4 f or eligibility  details , Sections  8.2 and 8.3 
for timing and Attachment  12.2 f or methodology.   The same methodology  and equipment  should be used for all VF examinations.   
 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 12 2021.01.30  Table  2 Part  1 - Schedule  of Visits  and Procedures:   Days  1 and 2 
Outcome  Assessment  Visits (Visit window  ± day) Day 1 Day 2 
Timepoint:  All examinations  for all visits  and timepoints  should be performed in  the 
order  listed  below  from top to bottom (refer  to Attachment  12.2 f or details  on how to 
perform procedures)  H0a 30 
minutes  
post -1st 
dose H2 H
4 H
8 H0 
Adverse  Event  Query X <——————————>  X 
Concomitant  Medications/ Treatments  X     X 
Postural  (Supine/Standing)  Blood  Pressure  & Heart  Rate X  X   X 
Urine  Pregnancy  Test      X 
Macroscopic  (Gross)  Hyperemia  X X X X X X 
Visual  Acuityb Xb     Xb 
Slit-Lamp  Biomicroscopic  Examination  X X X X X X 
Intraocular  Pressure  (IOP)c  X X X X X X 
Fundus  Exam  (including  cup/disc  ratio) (post -pupil  dilation)       X 
Confirm  Inclusion  / Exclusion  criteria  X      
Study  Medication  Assignment  X      
Study  medications  administered  at the site by site personnel  X      
Collect  subject  EXIT  status      X 
NOTE:   H = hour  (hour  0 = 07:00 to  09:00 hours ) 
a Pre- dose  
b Manifest  refraction performed at  Baseline (Day  -1) should be used at  Days  1 and 2 to obtain a correction for  visual  acuity  evaluation.   
Manifest  refraction(s)  may be repeated,  if in the opinion of the investigator,  it is necessary.   Visual  acuity  will be collected in  Snellen-
equivalent  units  using a logarithmic  (LogMar)  visual  acuity  chart . 
c  IOP should be measured before pupil  dilation (as  applicable)  and at  the same time (± 15 minutes)  each day  as the time established 
at baseline (day  -1, hour 0, between  07:00 and 09:00 hours).  
  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 13 2021.01.30  Table 3 Part  2 - Schedule  of Visits  and Procedures:   Day  1 to Day  14/Exit 
Outcome  Assessment  Visits (Visit window  ± day) Day 1 
(± 0 day) Days  4 (± 1 day) 
and 14 (± 2 days) 
Timepoint:  All examinations  for all visits  and timepoints  should be 
performed in  the order  listed  below  from top to bottom (refer  to 
Attachment  12.2 f or details  on how to perform procedures)  H0 30 
minutes 
post -1st 
dosea H2 H0 H2 H4 H8 
Text or phone  call from site reminding  subject  to dose  approximately  12 
hours  prior to morning  Hour  0 appointment     X    
Adverse  Event  Query X   X    
Subject  Comfort  of Eye Drops  Evaluation  (administered  by designated  site 
personnel)  (Day 1 and Day 14/Exit  only)  X  X    
Concomitant  Medications/Treatments  X   X    
Postural  (Supine/Standing)  Blood  Pressure  & Heart  Rate X  X X X   
Non-fasting  Laboratory  assessments  (CBC  with differential,  Blood  
Chemistries,  Urinalysis)  (Day  14/Exit  only,  following  final dose)     X 
Electrocardiogram  (Day  14/Exit  only)     X   
Urine  Pregnancy  Test (Day  14/Exit  only,  following  final dose)    X 
Macroscopic  (Gross)  Hyperemia  X X X X X X X 
Pupil  Size (Day  14/Exit  only)      X X   
Visual  Acuityb Xb   Xb    
Contrast  Sensitivity  (Day  14/Exit  only)     X    
Slit-Lamp  Biomicroscopic  Examination  X X X X X X X 
Intraocular  Pressure  (IOP)c  X X X X X X X 
Visual  Fieldd (Day  14/Exit  only)     X 
Fundus  Exam  (incl.  C/D ratio)  (post -pupil  dilation)  (Day  14/Exit  only)       X 
Confirm  Inclusion  / Exclusion  criteria  X       
Randomize  subject  / Dispense  study  medication  (for first dose)e X       
Study  medication  administered  by site personnel  X   X    
Collect  subject  EXIT  status  (Day  14/Exit  only)       X 
NOTE:   C/D = cup/disc;  H = hour (hour  0 = 07:00 to  09:00 hours)   
NOTE:   The night  before postbaseline visits,  evening dosing should occur  approximately  12 hours  (between  19:00 and 21:00 hours)  prior 
to hour 0 of the subject’s  next morning’s  visit) 
a Subject  Comfort  of Eye Drops  Evaluation will be performed within  30 minutes  post-morning dose.  
b Manifest  refraction performed at  Baseline should be used at the days  1, 4 and 14 visits to  obtain a correction for  visual  acuity  
evaluation.   Manifest  refraction(s)  may be repeated,  if in the opinion of the investigator,  it is necessary.  
c IOP should be measured before pupil  dilation (as  applicable)  and at  the same time (± 15 minutes)  each day  as the time established 
at baseline (day  -1, hour 0, between  07:00 and 09:00 hours).  
d The same methodology  and equipment  should be used for examinations  of VF performed throughout  the study.   Visual  Field  
evaluation can occur  at any time after the Hour  2 examination and prior to pupil  dilation for  fundus  examination  at Hour  8. 
e Give a single bottle of  study  medication to  subject  at the end of the visit 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 14 2021.01.30  1. Background  and Rationale  
1.1. Background  
Ocular  hypertension, or chronically elevated  intraocular  pressure (IOP),  is a major  risk factor  
for optic nerve injury and  sight loss associated  with  glaucoma ( AGIS,  2000; Heijl et  al, 
2002); t herefore,  a primary  goal of glaucoma management  is to reduce IOP.   Brimonidine 
(ALPHAGAN®, ALPHAGAN® P) is a potent alpha 2 adrenergic r eceptor  full agonist that  is 
used clinically  for long- term management  of increased  IOP.   However,  due to  its relatively  
short duration of action,  it is labelled  in the United  States  for administration  three times  daily  
(TID).   An alpha-agonist with an impr oved pharmacokinetic profile  could lead  to higher 
therapeutic drug  levels  or decreased  dosing which  may provide an  opportunity for better  IOP 
management.   
Whitecap  Biosciences  plans to  conduct an  initial 2- part clinical  study to  evaluate the safety  
and IOP-lowering effects  of AGN -227535 ophthalmic solution in  adult patients  with  primary  
open-angle glaucoma (POAG)  or ocular  hypertension (OHT).   Part  1 will be an  open- label,  
single-dose, dose- escalation  assessment  of up to  3 concentrations (0.05% 0.15%, 0.4%) of 
AGN-227535 administered  unilaterally  to assess initial safety,  tolerability  and IOP-lowering 
effects.   Results  from  Part 1 will determine  concentration(s)  to assess in  Part 2.  In  Part 2, up 
to 2 concentrations of AGN-227535 will be administered  bilaterally,  twice -daily  for up to  14 
days and  compared  to timolol as  the active control.  The non- clinical  data  package supports 
twice -daily  dosing of AGN-227535 0.4% for up to  28 days in  humans. 
1.2. Investigational Product   
AGN-227535 is  a pivalate ester  prodrug that  undergoes enzymatic hydrolysis in  the cornea to  
yield  the active metabolite,  AGN-222390.  Whereas  AGN-227535 is  only a weak  alpha2  
agonist, AGN-222390 is  a potent alpha2  adrenergic receptor  pan-agonist that  exhibits partial  
agonism at  the alpha2A  receptor  AGN -222390 is  also the 3-methyl hydroxylated metabolite  
of dexmedotomidine  a marketed  drug used  to produce short- term sedation  of patients  in the 
critical  care setting.   
A detailed  description of the chemistry,  non- clinical pharmacology and toxicology of AGN-
227535 is  provided in  the Investigator’s Brochure.  
1.3. Summary of Nonclinical Studies   
Nonclinical  studies have been  conducted  with  AGN-227535 to  assess pharmacology, 
pharmacokinetics  and toxicology (both locally  and systemically)  from  ocular  and oral 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 15 2021.01.30  administration  using various models including in  vitro, rat,  rabbit, dog, and  nonhuman 
primate s.  The focus  of the nonclinical testing  strategy  was 3-fold: to  establish  whether  AGN-
227535 is  differentiated  from  brimonidine relative  to attributes  that may  form  the basis  for a 
better  therapy  for IOP  management ; to validate  the conversion of  the prodrug to  the active 
metabolite  and to enable the conduct of clinical testing  of AGN-227535 with completion  of 
the prerequisite IND -enabling toxicology studies.   
Below  is a high- level  summary  of findings from  the nonclinical studies: 
• AGN-227535 is  a pivalate ester  prodrug that  is enzymatically  hydrolyzed as it passes  
through the cornea to  its active metabolite , AGN-222390; 
• AGN-222390 is  a potent alpha2  receptor  pan-agonist that  exhibits partial  agonism at  the 
alpha2A receptor  whereas  its parent,  AGN -227535, exhibits only weak  activity ;  
• AGN-222390 may  offer  advantages  over  brimonidine including less  potential for receptor  
down regulation (tachyphylaxis) and  a longer duration of IOP  reduction ; 
• Pharmacological  and pharmacokinetic evidence indicate  that AGN-222390 is the 
pharmacologically active  moiety ; 
• Ocular  instillation  of AGN-227535 is  well  tolerated  at the proposed clinical 
concentrations  and did not result  in adverse morphological changes ; 
• Systemic  effects  of AGN -227535 are largely  the known pharmacologic effects  of alpha2  
receptor  agonists and  include decreased  intestinal motility,  arterial  hypotension, 
bradycardia, and  sedati on.  In  some cases,  these were transient.  The pharmacologic 
systemic  adverse effects  are monitorable and reversible.  At higher doses than  the planned 
human equivalent starting  dose, adverse cardiovascular  effects  and/or decreased  GI 
motility  were the likely cause(s)  of death  observed following oral  administration  in 
rats.  The lower  systemic  exposure achieved  with topical  ocular  dosing suggests that  
cardiovascular  effects  are unlikely to  occur  with  the topical  dose (up  to 0.4%) and  dosing 
frequency  (twice -daily)  in this clinical  study; 
• Morphological changes  in the dog testes  and epididymides were observed at the highest 
dose tested  in a 14- day oral toxicity  study but not in the 1-month oral  toxicity  study at  
equivalent or higher doses; 
• Overall,  systemic  effects  of topically  applied  AGN -227535 at  concentrations of up to  
0.4% dosed twice  daily  are not expected  in humans given the administration  of a 
relatively  small administered  dose and a much  larger  central  volume compared  to the 
toxicology species ; 
• AGN-227535 and  AGN-222390 are not mutagenic or clastogenic.  
Details  of the non- clinical pharmacology, pharmacokinetics and  toxicology of AGN -227535 
is provided in  the Investigator’s Brochure. The non- clinical  profile  of AGN -227535 supports 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 16 2021.01.30  the planned twice -daily  dosing regimen  of concentrations of up to  0.4% and  the 2- week  study 
duration in  this clinical  study.  This study will be conducted in  compliance with the protocol, 
International Conference on Harmonization  guidance and  Good Clinical Practices.   
1.4. Benefit/Risk  Assessment  
This is the first  clinical  study of AGN -227535 in  humans; the potential benefits  may  be 
identifying an  alpha-agonist with  a longer duration of action  and a better  safety  profile  than  
currently  available alpha-agonist treatments  for IOP  loweri ng.  D etailed  information  about 
the potential and/or known risks  and potential adverse events  of AGN-227535 may  be found 
in the Investigator’s Brochure .  
2. Study  Purpose,  Objectives,  and Clinical  Hypothesis(es)    
Overall  Study  Purpose   
The purpose of this  study is  to assess initial ocular  and systemic  safety  in humans of AGN-
227535 ophthalmic solution and  to assess its  potential  to lower  IOP in subjects with  
glaucoma or ocular  hypertension.  
Study  Objective(s)  
The objective of this  study is  to assess the safety,  ocular  tolerability  and IOP-lowering effects  
of AGN -227535 in  adult subjects  with  primary  open -angle glaucoma or ocular  hypertension. 
Clinical Hypotheses   
Parts  1/2: AGN-227535 has  an acceptable safety  and tolerability  profile.  
Part 1: The IOP-lowering effects  of at  least  1 concentration  of AGN-227535 are 
sufficient  for evaluation  to proceed  to Part 2;  
Part 2: The IOP effects  of at least  1 concentration  of AGN -227535 demonstrate 
adequate IOP lowering; 
3. Study  Design  and Rationale  
Study  Design  Description:   This  is a 2-part study designed to  evaluate the  safety,  tolerability  
and IOP-lowering effects  of AGN -227535 in  subjects with  primary  open- angle glaucoma 
(POAG)  or ocular  hypertension (OHT).    Approximately 100 subjects  are planned  to be 
enrolled  at up to  approximately 5 study centers  in the United  States.  
In P art  1, an open- label  dose- escalation  of AGN-227535 0.05%, 0.15% and  0.4% is  planned 
in order to  assess initial safety,  tolerability  and IOP-lowering effects .  Approximately 6 
subjects  will be exposed to a single dose (to  one eye)  at each  concentration  level.   Between  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 17 2021.01.30  cohorts, all  available data  will be used  to assess the appropriateness to  pursue the next 
concentration.  Approximately 25 subjects  will be screened  so that 18 subjects  complete  the 
study.   
In Part 2, In  addition to  the primary  analysis  of the within -group mean  IOP change from  
baseline,  a parallel  comparison  of AGN-227535 with  timolol 0.5% is  planned .  Study 
treatments  will be administered  twice -daily  for 14 days.  Up  to 2 investigational doses will be 
chosen  based  on results  from  Part 1.  Subjects  will be randomized  in a 2(:2):1 ratio  to receive 
one of up to  two concentrations of AGN-227535 (based  on results  from  Part  1) or timolol 
ophthalmic solution 0.5% and  will be stratified  based  on IOP  at Baseline,  Hour 0 (≤  25 mm 
Hg versus > 25 mm Hg).   Approximately 24 subjects per  AGN-227535 group  and 12 su bjects  
for the timolol group will be given study treatment.   If 2 investigational doses are selected:  
approximately 75 subjects  will be screened  so that 60 subjects  complete  the study.  
For both Parts  1 and  2, potential subjects  will be screened  within  the 50 days prior to  
initiation  of treatment.   Thus, the total duration of study participation  for each  subject  is up to  
2.5 months which  includes 4 (Part  1) and  5 (Part  2) in -clinic  visits .  The visit schedule 
requires  day-long visits  at some time  points to  perform  sufficient  clinical  assessments.   The 
primary  efficacy  endpoint (Part  2) is  IOP change from  baseline at  each  time -matched  hour at 
Day 14/Exit. 
Subject  s afety  will be monitored  throughout the study.  
Rationale for  the Study  Design:   Part  1 of this first  in-human study will be conducted in  a 
dose- escalation  approach  to assess the initial safety,  tolerability  and IOP-lowering effects  of 
AGN-227535 following a single dose.  Part  2 will be conducted as a 14- day assessment  of 
the safety,  tolerability  and IOP-lowering effects  of AGN-227535 dosed bilaterally  BID  to 
evaluate the short -term potential to  lower  IOP with  an acceptable safety/tolerability  profile.  
Timolol,  an accepted  standard of care treatment , will be used  as the control in  Part 2. 
Rationale for  Dose  and Route  of Administration:  Alpha-2 agonists are well-characterized .  
For  AGN-227535 approximately  44- to  714- fold safety  margins were derived  from  the 
systemic,  local  (ocular),  cardiovascular,  and pulmonary toxicology studies in  rats and/or dogs 
(Studies TX11082, TX11057, TX11154, and TX11120); these margins are  considered to  be 
sufficient  to support the clinical starting  dose of 0.05% AGN -227535 with  up to  BID  bilateral  
administration  in subjects  with  POAG or OHT.   As a topical  eyedrop, the route of 
administration  is considered  appropriate.  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 18 2021.01.30   Rationale for  Duration of Observation:  As  the first -in-humans study, it is appropriate to  
take a measured  approach with  limited  exposure to  confirm  the non- clinical results.   Alpha-
agonists are well -characterized  in humans and based  on results  of Part  1, a planned 14- day 
assessment  is appropriate. 
3.1. Study  Endpoints  
3.1.1. Primary  Efficacy  Endpoint(s)  
The primary  efficacy  endpoint is  mean  change from  baseline in  IOP at each  time -matched  
hour of Day  14/Exit (Hours  0, 2, 4 and  8).   
3.1.2. Secondary  Efficacy  Endpoint(s)  
Mean  IOP at Day  14/Exit.   
3.2. Methods  for Randomization,  Stratification,  Masking,  and 
Minimization  of Bias  
3.2.1. Randomization and  Stratification  (Part  2 Only)  
Subjects  will be randomly assigned  to 1 of up to  3 treatment  arms  (based  on results  from  Part 
1) in a 2(: 2):1 allocation  ratio to receive 1 of up to  2 AGN-227535 concentrations or timolol.   
To ensure balance of  elements  that could influence the IOP -lowering effects  across  treatment 
groups, the ran domization  will be stratified  by baseline (Hour 0) IOP  (≤25 mm Hg;  >25 mm 
Hg). 
The randomization scheme will be prepared  by Whitecap  Biosciences  Biostatistics  or its’  
designee.  The IWRS,  a module within  eDC,  will be used  to confirm  Baseline IOP  eligibility  
and in Part 2 only, stratification  and randomization of subjects.      
3.2.2. Masking  
Part 1: Subject  treatment  will not be masked.   If both eyes  qualify, the eye with  the higher 
IOP at Baseline (Day  -1) Hour 0 will be the study eye and  will receive study medication.   If 
both eyes  have the same IOP value at  this timepoint,  the right eye will be the study eye.    
Part 2: Subject  treatment  will be double- masked;  neither  the investigator nor  the staff  or 
subject  will be aware of treatment  assignment.  All study treatments  will be provided in  
similarly -appearing  bottles  with  the same colored  bottle  caps  and identical  cartons  to 
maintain  masking of the study. 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 19 2021.01.30  3.2.3. Minimization  of Bias 
The study design is  that of a well -controlled clinical  trial that  includes elements  necessary  for 
a valid  ascertainment  of the effectiveness  of treatment.   Part  2 of the study is  randomized  and 
double- masked  to minimize  investigator and  subject bias.   A parallel -group design eliminates  
possible confounding effects  that are inherent in  other  study designs (eg,  crossover).  The 
selection  of subjects,  study endpoints, and  therapy  are in  general  similar  to studies that  
established  the safety  and efficacy  of other  IOP-lower ing treatments of subjects  with  
glaucoma or ocular  hypertension.  Subjects  who  are chronically  treated  with  ocular  
hypotensive medications  will be required  to undergo appropriate washout periods prior to  
study entry  to eliminate  residual  effects  of other a ctive  ocular  hypotensive medications.  
3.3. Treatment Stopping  Rules and Discontinuation  Criteria   
3.3.1. Treatment  Stopping  Rules   
There are no specific treatment stopping rules.   On an ongoing basis,  all available  safety  data 
will be reviewed  by the  sponsor.  If two  or more  adverse events  of the same kind that  are 
severe in  nature and  considered  possibly study drug related  occur, a decision  will be made as  
to whether  to stop enrollment of the cohort (Part  1 only), to  add subjects  to a lower  
concentration  cohort (Part  1 only), to  stop the study  and exit all subjects,  or to  continue the 
study and  proceed  as planned (see Section  3.4 for d etails  on decision  making). 
3.3.2. Discontinuation Criteria  
Subject  Discontinuation 
Whitecap  Biosciences,  or the investigator, may  decide to  discontinue subjects who  are 
enrolled  into the study but who  had significant deviation  from  protocol- specified  
inclusion/exclusion criteria.  
If a subject  meets  any of the following criteria , s/he  must be exited  from  the study (see Early  
Exit Procedures,  Section  8.9).    
• The investigator or Whitecap  Biosciences  deems  that it is  unsafe for the subject  to 
continue in  the study; 
• Subject  indicates  that s/he no longer want  to participate  in the study. 
Subjects  will be discontinued from  the study under the following circumstances:   if a female 
subject  becomes  pregnant during th e study, the investigator  will notify Whitecap  Biosciences  
immediately  after  the pregnancy is  confirmed, the  subject  should not receive further study 
treatment  and she must be  exited  from  the study and the pregnancy  followed to  term  (see 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 20 2021.01.30  Section  8.9 for Early  Exit  Procedures  and Section  6.4.3 for Procedures  for Pregnancy  
Follow-up and  Reporting).  
Subjects  who are exited  before  completing  the study may  be replaced  following consultation 
with sponsor. 
Study  Discontinuation 
The study may  be stopped at  a study site  at any time  by the site  investigator.  Whitecap  
Biosciences  may  stop the study (and/or the study site)  for any  reason  with appropriate 
notification.  
3.4. Decision  Making  During  Part s 1 and 2 
No formal  Data Monitoring Committee  will be established  for this  study.  Prior  to each  dose-
escalation  step in Part 1, all available data will be reviewed  to determine  if the next dose 
should be assessed  or if  the study should be stopped.  If the study pro ceeds  to Part 2, the 
determination  of doses to  evaluate will be based  on an unmasked review  of all  available data 
from  Part 1. 
All decisions to  proceed  or stop the study at  any time  will be made by a committee  
comprised  of the Medical  Monitor, the Head  of Clinical  and the Chief  Executive Officer.   
Dose selection  to be studie d in Part 2 will be made by the same committee :  an unmasked 
review  of all Part 1 safety,  tolerability  and IOP effect  results  will be performed  to determine  
if Part 2 should be performed  and if yes, which  dose(s)  should be assessed .  All decisions will 
be documented.   
4. Study  Population   
Prospective approval of protocol deviations to  recruitment and  enrollment criteria,  also 
known as  protocol waivers  or exemptions, is  not permitted.  
The study population consists of adult subjects  with  POAG or OHT  (but who  are otherwise 
healthy).  Subject  eligibility  will be based  on the entry  criteria  below.   
4.1. Inclusion  Criteria  
The following are requirements  for enrollment into  the study:  
General:  
1. Male or female at  least  18 years  of age at  the time  of consent. 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 21 2021.01.30  2. Female subjects  must agree to  use an  acceptable method of contraception (see Section  
6.4 for pregnancy  considerations and  contraceptive requirements).  
Type  of Participant  and Disease  Characteristics:  
3. Subject  who: 
a. Is able and  willing  to follow study instructions and  likely  to complete  all required  
study visits ; 
b. Has chronic POAG or OHT  in each  eye and IOP  is likely  to be controlled on 
monotherapy; 
c. If on IOP -lowering medication,  is willing  to withhold  his/her IOP -lowering  
treatments  for the duration  of the study and  can do so  without significant risk,  in the 
opinion of the investigator; 
d. If on IOP -lowering medication,  has been  appropriately washed  out of all IOP-
lowering medications  prior to  Baseline (Day  - 1) (see Sectio n 6.2); 
e. At Baseline (Day  -1), meets  the following criteria  in at least  1 eye (and  in the same 
eye for all hours indicated  below):  
1. An IOP ≥ 24 mm Hg  and ≤ 34 mm Hg  at Hour 0; and   
2. An IOP ≥ 22 mm Hg  and ≤ 34 mm Hg  at Hours 2, 4 and  8. 
f. Has an IOP ≤ 34 mm Hg  in the fellow  eye at Baseline (D ay-1) Hours 0, 2, 4 and  8 
g. Has a best -corrected  visual  acuity  (BCV A)  score equivalent (using a logarithmic  
(LogMar) visual acuity  chart ) to Snellen  acuity  of 20/100 or better  in at least  1 eye 
and of 20/200 or better  in the fellow  eye, using a logarithmic  visual acuity  chart  at 
Screening  and Baseline (Day  -1);  
h. Is in good general  health  [as determined  by the  investigator from  medical  history 
and physical examination  findings, non- fasting  blood analysis  (complete  blood 
count with  differential,  blood chemistry),  urinalysis], and  12 lead -ECG  results  are 
within  reference range or acceptable to  the investigator prior to  randomization.  
Note:   For the screening  laboratory evaluation, subjects  may have laboratory  tests  
repeated  once for reassessment  at the discretion  of the investigator prior to  
randomization. The investigator must review  the screening  results  to confirm 
subject  qualification  for study entry . 
Informed  Consent  and Written  Authoriza tion 
4. Written  informed  consent  of the subject  has been  obtained prior to  any study- related  
procedures.  
5. Written  documentation has  been  obtained in  accordance with  the relevant  country and  
local  privacy  requirements,  where applicable (eg,  Written  Authorization for  Use and 
Release of Health  and Research  Study Information).  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 22 2021.01.30  4.2. Exclusion  Criteria  
If any  of the following criteria  are met,  the subject  is not eligible  for participation  in the 
study: 
Medical  Conditions  
1. Uncontrolled systemic  disease. 
2. History  of orthostatic  hypotension. 
3. Female who  is pregnant, nursing, or planning a pregnancy, or female of childbearing 
potential not using a reliable  means  of contraception (see Section  6.4). 
4. Abnormal anatomy  of nasolacrimal  drainage system  (eg, nasolacrimal  duct obstruction). 
5. History  of chronic alcohol  consumption or drug addiction. 
6. Contraindications to  topical  beta- blocker  therapy including bronchial asthma;  a history 
of bronchial asthma;  chronic obstructive pulmonary disease;  second- or third -degree 
atrioventricular  block; overt cardiac failure ; cardiogenic shock. 
7. History  of or current  diagnosis of cardiac arrhythmia. 
8. Heart  rate < 55 beats  per minute  while  in a resting  supine position. 
9. Blood pressure  decrease from  the supine measurements  of at  least  20 mm Hg  (systolic)  
or of at  least  10 mm Hg  (diastolic)  after  3 minutes  of standing. 
10. Systolic  blood pressure  < 90 mm Hg  while  in a resting  supine position. 
Ophthalmic  History  / Conditions  
11. Types of glaucoma other  than chronic POAG (eg, uveitic ; pigmentary; PXE,  traumatic ; 
angle-closure, including those who  have had  an iridectomy  and/or iridotomy ).  
12. Surgical  intervention for glaucoma at  any time  or laser  intervention  for glaucoma within  
the 12 months prior to  Screening.    
13. History  of ocular  neoplasia,  uveitis,  or herpetic ocular  diseases . 
14. History  (within  6 months prior to  Baseline [Day  -1]) of any  intraocular  or refractive 
surgery in  either  eye. 
15. Evidence of cataract  surgery  resulting  in complications  (eg, capsular  rupture) in  the 
study eye.   
16. History  or evidence of severe ocular  trauma in  the study eye. 
17. Moderate or advanced  findings of glaucoma on visual field  examination; visual field  
loss which, in  the opinion of the investigator, is  functionally significant or shows 
evidence of  progression ( based  on 2 visual field  examinations ) (see Sections 8.2 and  8.3 
for timing of visual field  examination  requirements).    
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 23 2021.01.30  Prior/Concomitant Therapy  
18. Current  or anticipated  use of any  ocular  medications  (including periocular,  intraocular,  or 
sub-Tenon’s administration ) or other medications  (eg, oral)  for ophthalmic indications 
outside  of those of the study protocol from  2 months  prior  to Screening  through Day  
2/Exit  (Part  1) or Day  14/Exit (Part  2).  NOTE :  If required, IOP -lowering  medications  
with shorter washout durations may  be used  during the washout period shown  in Table  5. 
19. Introduction or anticipated  alteration  of existing  chro nic systemic  medications  that may  
have a substantial effect  on IOP  (eg, systemic  beta-blockers, carbonic anhydrase 
inhibitors or cholinergic agonists) from  2 months  prior  to Screening  through Day  
2/Exit  (Part  1) or Day  14/Exit (Part  2). 
20. Current  or anticipa ted use of oral,  intramuscular,  intravenous, intravitreal,  periocular,  or 
topical  ophthalmic corticosteroids from  2 months  prior  to Screening  through Day  
2/Exit  (Part  1) or Day  14/Exit (Part  2) (see Section s 6.1 and  6.3). 
21. Treatment  with  any non- ocular  alpha agonists, alpha antagonists (including medications  
for benign prostate hyperplasia),  anticholinergics, sedative medications  (including 
antihistamines,  benzodiazepines, or opiate-type medications),  or cold  medications  that 
could confound the study results  within  2 weeks  prior  to Baseline  (Day  -1) or 
anticipated  use during  the study  (see Sections  6.1 and  6.3). 
22. Use of adrenergic augmenting antidepressant  drugs, monoamine oxidase inhibitors 
(MAOIs),  serotonin norepinephrine reuptake inhibitors (SNRIs),  tricyclic  
antidepressants  (TCAs) within  30 days prior  to Screening  or anticipated  use during  
the study  (see Secti ons 6.1 and  6.3). 
23. Subject  has a sleep  disorder or has  had excessive daytime  somnolence within  30 days 
prior  to Screening . 
24. Use of sedative-hypnotics or other agents (including over the counter) for insomnia 
within  10 days prior  to Screening  or anticipated  use during  the study  (see Sections  
6.1 and  6.3). 
25. Consumption of alcohol-containing beverages  or products within  72 hours  prior  to 
dosing  on Day  1 or anticipated  consumption within  72 hours  prior to  a study  visit .  
26. Blood donation or equivalent blood loss of ≥ 450 mL  within  90 days prior to  Day  1. 
Prior/Concurrent  Clinical Study  Experience 
27. Previous randomization in  Part 2 of this  study. 
28. Concurrent enrollment in  an investigational drug or  device study or participation  in such  
a study within  the 30 days  prior  to Screening . 
Diagnostic Assessments 
29. Known  allergy  or hypersensitivity to  the study medication  or their  components. 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 24 2021.01.30  30. Known  allergy,  hypersensitivity  or lack  of efficacy  with  brimonidine (ALPHAGAN®, 
ALPHAGAN® P).  
31. Kn own  allergy  or contraindication to  use of any  diagnostic agents . 
32. Anticipated  wearing  of contact  lenses  in either  eye during the study: 
o Use of rigid  gas permeable (RGP) lenses  or hard  contact  lenses  should be 
discontinued at  least  1 week  prior to  Baseline (Day  -1); 
o Discontinue use of s oft contact  lenses  at least  24 hours prior to  Baseline (Day  -1). 
33. The followin g ocular  surface findings: 
o Ocular  hyperemia in  either  eye,  on either  macroscopic or slit- lamp  examination, 
greater  than  +1 ( mild) at Screening  or greater  than  or equal  to +1 ( mild) at Baseline 
(Day  -1) at Hour 0, based  on a bulbar hyperemia grading guide (standard  
photographs) provided by  the sponsor; 
o Active  ocular  surface  findings other than  hyperemia in  either  eye,  on either  
macroscopic or  slit-lamp  examination, greater  than  or equal  to +0.5 (trace)  at 
Baseline (Day  -1) at  Hour  0. 
34. Any ocular  symptom at  Baseline (Day  -1) at  Hour  0. 
35. Active  ocular  disease (eg, blepharitis , dry eye,  ocular  seasonal  allergies)  that would 
interfere with  the interpretation  of the study data in  either  eye. 
36. Corneal  or  other ocular  abnormalities  that would preclude accurate reading  with  an 
applanation tonometer (eg, corneal  ectasias,  corneal  graft,  significant corneal  scarring) . 
37. Contraindication to  pupil dilation . 
Other Exclusions 
38. Anticipated  need  to participate  in any activity  that may  cause irritation  to the eye (eg,  
swimming,  smoking) during the study. 
39. Anticipated  need  to engage in  strenuous physical activity/exercise  within  24 hours prior 
to a study visit, or to  change an  established  exercise routine during the study. 
40. Subject  has a condition or is  in a situation  which, in  the investigator's opinion, may  put 
the subject  at significant risk, confound the study results,  or interfere  significantly  with  
the subject 's participation  in the study. 
4.3. Lifestyle Considerations  
Durin g the study, subjects  will be advised  to: 
• Refrain  from  activities  that may  cause irritation  to the eye (eg,  swimming  or smoking); 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 25 2021.01.30  • Refrain  from  engaging in  strenuous physical activities/exercise within  24 hours prior to  a 
study visit or changing established  exercise routine during the study; subjects  may  
participate  in light recreational  activities  during the study (eg,  watching  television,  
reading); 
• Refrain  from  use of types of medications  listed  in exclusion criteria.   If used, document, 
in subject’s  Source Document  /Case Report Form ; 
• Refrain  from  drinking more  than  ½ cup  of liquid  for one hour prior to  IOP measurements  
on study visit days. 
4.4. Screen  Failures 
Screen  failures  are defined as  subjects  who  consent  to participate  in the clinical  study but are 
not subsequently entered  into the study.  A minimal set  of screen  failure  information  is 
required  to ensure transparent  reporting of screen  failure  subjects  to meet  the Consolidated 
Standards of Reporting Trials  (CONSORT)  publishing requirements  and to respond to  
queries  from  regulatory authorities.  Minimal information  includes demography, screen  
failure  reasons , eligibility  criteria,  and any serious adverse event  (SAE).  
Individuals who  do not meet  certain  eligibility  criteria  (eg, IOP)  for participation  in this study 
(screen  failure)  may  be re-screened  once.   Each  case must be discussed  with  Whitecap  
Biosciences  for re-screening  consideration.  Re -screened  subjects  should be assigned  the 
same participant  number as for the initial screening.  
4.5. Rationale  for Inclusion  and Exclusion  Criteria   
The inclusion criteria  and exclusion criteria  [11-17] are designed  to enroll adult subjects  with  
OHT  or mild  POAG, as  these subjects  will be unlikely to  require  other treatment 
interventions during the study. 
Exclusion criteria  [18-26] are designed  to exclude  subjects  who se study results  could 
interfere with  the interpretation  of the efficacy  results.  Exclusion criter ia [29-38] are designed 
to avoid including subjects  with  ocular  conditions that  may  interfere with  the interpretation  
of the study results.  
5. Study  Treatments 
5.1. Investigational Product  
Investigational Product  Description  
The following study treatments  will be used  in this study (Study treatments  1, 2 and  3).  For 
study purposes, these treatments  are referred  to as Investigational Products (IP).   AGN-
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 26 2021.01.30  227535/WB007 ophthalmic solutions at  concentrations of 0.05%, 0.15% and 0.4% are the  
planned study treatments.    In Part 2, Timolol maleate ophthalmic solution 0.5% will be used  
as a control (Study treatment 4).   A description of the formulation  characteristics  for AGN-
227535/WB007 is  given in  Table  4. 
Table  4 Formulation Characteristics  for AGN-227535/WB007  
(Study  Treatments  1-3) 
AGN-227535 Formulation Name  Formulation 
Number  Strength  
0.05%  Ophthalmic  Solution  11024X  0.05%  w/v* 
0.15%  Ophthalmic  Solution  10183X  0.15%  w/v 
0.4%  Ophthalmic  Solution  10184X  0.4%  w/v 
*w/v  = mass/volume    
The vehicle used  for all AGN-227535 formulations  include the following:  benzalkonium 
chloride (BAK)  0.02% w/v  (200 ppm), Solutol®, edetate disodium, citric  acid  monohydrate, 
sodium phosphate dibasic heptahydrate, glycerin, hydrochloric acid,  sodium hydroxide, and  
water  for injection.    
Study  T reatment  #4 - Timolol maleate ophthalmic solution 0.5%:  contains timolol 0.5% 
(6.8 mg  timolol maleate),  mono basic and  dibasic sodium phosphate, hydrochloric acid  
and/or so dium hydroxide to  adjust pH,  purified  water  and benzalkonium chloride 0.005%. 
5.1.1. Preparation/Handling/Storage/Accountability 
Investigational Product  Storage 
The i nvestigator or designee must confirm  appropriate temperature conditions have been  
maintained  during transit for all  study treatments  received  and any discrepancies  are reported  
and resolved  before use of  the study medications .  Study product must be stored  in a secure,  
environmentally controlled, and  monitored (automated)  area in  accordance with  the labeled  
storage conditions with  access  limited  to the investigator and  authorized site  staff.    Study 
product must be stored  in their  original containers  at room temperatu re (between  15ºC to  
25ºC; 59ºF to  77ºF) with  a calibrated  continuous temperature monitoring device.  Sites  must 
report  any temperature excursion to  Whitecap  Biosciences  and avoid dispensing and/or 
administering  the impacted  study product, by isolating  the product, until receiving  further 
instructions from  Whitecap  Biosciences  (see Study Reference Manual  for more  information). 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 27 2021.01.30  Investigational Product  Kit 
Each  IP kit will contain  a single bottle  of study treatment  (Part  1) and  2 bottles of study 
treatment  (Part  2).  E ach subject  will be allocated  1 kit.   Additional kits  will be provided to  
the site  in the event  of loss/damage.  In  Part 2, each  bottle  of study treatment will be 
packaged  in a unit carton.   Each  IP kit will be stored  in secondary packaging .  Clinical 
supplies for each  subject  will be labeled  with  a kit number associated  with the subject  
randomization.   
To assign  kits in Part 1, designated  site personnel will pull a kit from  the provided inventory 
for the given cohort.  To assign  kits in Part 2, designated  site personnel will  use IWRS  to 
obtain the specific kit number(s).   The site will receive the IWRS  confirmation  notificatio n 
for transaction s.  All notifications  are to  be maintained  with  the study source documents (s ee 
Study Reference Manual  for more  information). 
Appropriately qualified  s tudy site  personnel will administer/dispense  study medications  as 
indicated  in Section  8.4. 
Investigational Product  Preparation  
Not applicable.   
Investigational Product  Inventory   
The investigator, institution,  or the head  of the medical  institution  (where  applicable)  is 
responsible for investigational product accountability,  reconciliation,  and record  maintenance 
(ie, receipt,  reconciliation,  and final  disposition records).  
Further guidance an d information  for the final  disposition of unused investigational product 
are provided in  the Study Reference Manual . 
5.2. Study  Treatment Administration  
5.2.1. Study  Treatment  Regimen  and Dosing  
The principal investigator  or delegated  study personnel will instruct subjects  on proper 
dosing techniques of ocular  medications.   In Part 1 and  on study visit days in  Part 2, the 
morning dose of study medications  will be admin istered  by the site,  and dosing will occur  at 
approximately the same time  of day  (hour 0 between  the hours of 07:00 and  09:00) for a 
given subject .  Also  in Part  2, subjects  will self -administer  the study medication  as follows:  
all other morning doses (between  07:00 and  09:00 hours) and  all evening  doses (between  
19:00 and  21:00 hours) at  approximately the same  time  of day  each  morning and  evening.  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 28 2021.01.30  Study visits  should be scheduled  to occur  approximately 12 hours following the evening dose 
the night bef ore a study visit.  
5.2.2. Treatment  Compliance  
The IP must be dispensed/ administered  only to  the study subject  by appropriately  qualified  
site personnel.  The IP is to be used  in accordance with the protocol for subjects  who  are 
under the direct  supervision of an  investigator. 
Part 1:  The study treatment  will be administered  by site  personnel.   
Part 2:  Subjects  will be instructed  on proper dosing techniques and  site personnel will 
periodically  remind  subjects to  take their  treatments  (via text message or phone call) , 
(at a minimum, the night before  a scheduled  follow -up visit). 
6. Concomitant  Treatments  and Medications  
Any medication  or vaccine (including over- the-counter  or prescription medicines,  vitamins,  
and/or herbal  supplements) that  the subject  is receivin g after  study treatment dosing is  
initiated  must be recorded  along with: 
• Reason  for use; 
• Dates  of administration  including start  and end dates ; 
• Dosage information including dose and  frequency . 
The Medical  Monitor should be contacted  if there  are any  questi ons regarding  concomitant 
treatments  and medications.  
6.1. Prohibited  Treatments  and Medications  
The decision  to administer  a prohibited treatment  and/or medication  is done with  the safety  
of the study participant  as the primary  consideration.  When  possible, W hitecap  Biosciences  
should be notified  before the prohibited treatment  or medication  is administered.  
The following medications,  classes  of medications,  and treatment  procedures  are not 
permitted  as concurrent  therapy  during the study: 
• Medication,  conditions, or treatments  that are contraindicated  to brimonidine;  
• Treatment  with  any alpha agonists, alpha antagonists (including medications  for benign 
prostate hyperplasia), anticholinergics, sedative medications  (including antihistamines,  
benzodiazepines, or opiate-type medications),  or cold medications ;  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 29 2021.01.30  • Use of adrenergic augmenting antidepressant  drugs, MAOIs,  SNRIs,  or TCAs,  or drugs;  
• Us e  of oral,  intramuscular,  intravenous, intravitreal,  periocular,  or topical ophthalmic  
corticosteroids.  NOTE :  intra-articular,  inhaled, nasal,  and dermal  corticosteroids are 
permitted ; 
• Use of sedative-hypnotics or other agents (including over the count er) for insomnia; 
• Us e  of any  other ophthalmic topical  medications  or oral  medications  for ophthalmic  
indications.  NOTE:  artificial tears  are allowed  during study (see S ection  6.3 for 
acceptable usage) ; 
• Excessive consumption of  alcohol or caffeine; 
• Wearing  of contact  lenses . 
6.2. Washout/Waiting  Period  
The washout/waiting  period between  Screening  and Baseline is  4 to 50 days.  The duration of 
this period is  dependent upon whether  a subject  is taking IOP -lowering medications  at 
Screening.  
6.2.1. Washout Period   
Eligible  subjects  who  are being treated  with  IOP-lowering medication(s)  in either  eye will 
begin washout of these medication(s)  following the  screening  visit.   The minimum washout 
period will be 4 days to  6 weeks  depending on the washout schedule below  (Table  5).  N ote:   
The time  from  Screening  to Baseline should not exceed  50 days.    
Table  5  Minimum  Washout Period  
Ophthalmic  Medication(s)  Minimum  
Carbonic  anhydrase  inhibitors  (topical  or systemic)  (eg, acetazolamide  [Diamox®],  dorzolamide  
[eg, Trusopt®],  brinzolamide  [eg, Azopt®],  methazolamide  [eg, Neptazane])  4 days   
Sympathomimetics  (eg, Dipivefrin,  [PROPINE®])  or Epinephrine  [eg, Epifrin®])  2 weeks  
Alpha -agonists  (eg, brimonidine  [ALPHAGAN®  P], apraclonidine  [Iopidine®])  2 weeks  
Beta-adrenergic  blocking  agents  (eg, timolol  [Timoptic®,  Timoptic  XE®],  levobunolol  
[BETAGAN®],  betaxolol  [Betoptic®, Betoptic -S®], metipranolol  [Opti- Pranolol®],  carteolol  
[Ocupress®]  and gene rics) 4 weeks  
Fixed -combination  therapy  (eg, Cosopt®,  COMBIGAN®)  4 weeks  
Prostamides,  prostaglandins,  and prostaglandin  analogs  (eg, bimatoprost  [LUMIGAN®],  
latanoprost  [Xalatan®],  travoprost  [Travatan®],  unoprostone  [Rescula®],  tafluprost  [Taflotan®])  6 weeks  
Rho Kinase  (ROCK)  Inhibitors  6 weeks  
 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 30 2021.01.30  6.2.2. Considerations During  Washout Period  
For a subject  on IOP -lowering medication(s),  to minimize  the effect  of the absence of IOP-
lowering therapy  during the washout period, the investigator  (at his/her discretion) may  
choose to  modify a subject ’s medication  regimen  to a medication  with  a shorter  washout 
duration rather  than  stop all  IOP-lowering medications  at once (eg,  while  undergoing the 
washout of a prostaglandin analog  [PGA]  (6 weeks),  a subject  may  be switched  to a carbonic 
anhydrase inhibitor which  has shorter washout duration (4  days) than  the PGA).   The 
duration of the washout period  must adhere to  the requirements  summarized  in Table  5 based  
on the medications  used  at the time  of Screening.  At the discretion  of the  investigator, for 
subjects  undergoing a washout period, consideration should be given to  interim safety  
evaluation  of IOP  at some time  during the washout period. 
6.2.3. Wai ting Period  
Subjects  who  are not taking any  IOP-lowering medications  at Screening  must have a 
minimum of 3 days between  the Screening  and Baseline  visits.   If a subject  has taken  
IOP-lowering medications  prior to  the scre ening visit,  then  s/he must also  adhere to  the 
appropriate washout period (See Table  5). 
6.3. Permissible  Medications and Treatments   
During the study, therapy  considered  necessary  for the subject's welfare  may  be given at  the 
discretion  of the investigator.   If the permissibility  of a specific medication/treatment  is in 
question, please contact  the Medical  Safety  Physician .   
Use of intra -articular,  inhaled, nasal,  and dermal  corticosteroids are permitted.  
Use of artificial tears  is permitted  providing the artificial tear  is not given within  30 minutes  
pre- or post-study treatment  administration.   Use  of artificial tears  will be documented in  the 
appropriate e CRF.  
Existing  use of chronic systemic  medications  that may  have a substantial effect  on IOP  (eg, 
systemic  beta-blockers, carbonic anhydrase inhibitors cholinergic agonists) are allowed  
providing the dosage has  been  stable  for at  least  3 months prior to  randomization and  remains  
stable  throughout the study.  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 31 2021.01.30  6.4. Pregnancy  and Contraception  Considerations  
Definition  of Female of Child -bearing  Potential   
For purpos es of this  study, a female will be considered  of childbearing potential unless she is  
permanently  sterilized  (ie, hysterectomy) or is  naturally  postmenopausal.  Natural  menopause 
is defined  as the permanent cessation  of menstrual  periods, determined  retros pectively  after  a 
woman  who  is at least  40 years  of age has  experienced  12 months or more  of amenorrhea 
without any  other obvious pathological or physiological cause.   Female subjects  who  have 
had a hysterectomy  or are  naturally  postmenopausal will not be required  to perform  a urine  
pregnancy test  or to  use contraceptives  during the study. 
6.4.1. Pregnancy  Considerations 
All female subjects  who  are of child -bearing potential will be advised  to avoid pregnancy and 
are required  to use methods of contraception considered  acceptable to  Whitecap  Biosciences  
during the study.   
 For information  about pregnancy reporting procedur es, see Section  6.4.3. 
6.4.2. Acceptable Contraception  
The investigator will review  the contraception  requirements  for the study with  each  subject.   
The following methods of contraception, if  properly used, are considered  acceptable for use 
to avoid pregnancy during  this study:  hormonal contraceptives  for females,  (ie, oral,  patch,  
injection,  implant); sterilization  (ie, bilateral  salpingectomy, bilateral  tubal ligation,  
vasectomy  with  the appropriate post- vasectomy  documentation of the absence of sperm  in 
the ejaculate);  intrauterine  devices/systems,  sexual  abstinence (when  this is the lifestyle  of 
the subject ), and the following barrier  methods (male  condom with  intravaginal  spermicide,  
diaphragm or cervical  cap with  spermicide,  vaginal  contraceptive ring).   Note:  spermicide  
alone is  not an  acceptable barrier  method. 
6.4.3. P rocedures  for Pregnancy  Follow- up and Reporting   
If a female subject becomes  pregnant during the study (or within  30 days post-study exit),  the 
investigator will notify Whitecap  Biosciences  (or designee)  immediately  after  the pregnancy  
is confirm ed.  The subject should not receive further study treatment  and she must be exited  
from  the study (see Section  8.9 for Early  Study Exit Procedures).    
The investigator will (1) notify the subject’s  physician that  the subject  was enrolled  in the 
study and  treated  with  an investigational drug AGN-227535 ophthalmic solution or with  
timolol ophthalmic solution, and  (2) follow the progress of the pregnancy  to term.   The 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 32 2021.01.30  investigator must document the outcome of the pregnancy  and provide a copy  of the 
documentation to  Whitecap  Biosciences.  
7. Study  Assessments  
This section  provides a high- level  summary  of the study assessments to  be performed.   For 
details  as to when  these assessments are performed,  see Section  8.  For a description  of  study 
procedures, examination  procedures, tests,  equipment and  techniques, see Attachment  12.2.  
F
or an  explanation of terms  and abbreviations, see  Tables  6 and 7.   
7.1. Demographics and Baseline  Characteristics 
• Age,  race (including categories  for ethnicity) , sex, iris color; 
• Medical  and ophthalmic histo ries; 
• Prior medications  and treatments ; 
• Physical  Examination ; 
• Ophthalmic  Examination . 
7.2. Efficacy Assessments   
• IOP:   IOP  will be measured  using a Goldmann Appla nation Tonometer (GAT)  and a 2-
person reading method. 
7.3. Safety Assessments  
• Adverse Events :  Adverse events  will be monitored throughout the study; 
• Physical Examination :  A physical examination  including height and  weight ;  
• Respiratory  rate and temperature  in a resting  seated  position;    
• Postural (Supine  and Standing)  blood pressure and heart  rate will be assessed  at 
specified  timepoints  and visits ; 
• Electrocardiogram  (ECG):   A standard  12-lead ECG  will be performed  at the specified  
visits  and timepoints.   ECGs  will be collected  as triplicate  recordings (within  
approximately 1 minute  apart)  and reviewed  by the  investigator.  A consulting 
cardiologist will confirm  the qualification  of the subject  prior to  dosing of subject ; 
• Non-Fasting  Laboratory Tests :  Complete  blood count with  differential,  blood 
biochemistry,  and urinalysis will be measured ; 
• Urine Pregnancy  Te st:  Female subjects  of childbearing  potential will have urine 
pregnancy tests  performed ; 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 33 2021.01.30  • Macroscopic Hyperemia  Evaluations :  Macroscopic bulbar conjunctival hyperemia will 
be graded  by the  investigator upon gross inspection  and compared  with  standard images ; 
• Pupil  size:  Using  the centimeter  ruler  on the near  card,  measure the subject's pupils to  
the nearest  0.5 mm in  size.   The pupil gauge on the  near  card may  also be used  to 
estimate  pupil diameter  per investigator preference ; 
• Vi sual  Acuity :  Visual  acuity  (in Snellen  equivalents) will be measured  for each  eye 
using a logarithmic  visual acuity  chart  (4-meter  distance).   Manifest  refraction  will be 
performed ; 
• Contrast Sensitivity  (Part  2 only) :  Contrast sensitivity  will be measured  for each  eye 
using a VectorVision  CSV1000 at  designated  sites ; 
• S lit -lamp  Biomicroscopy:   Biomicroscopic examinations will be performed  using a slit 
lamp  through an  undilated pupil.  The examinations  will include evaluation  of the 
condition of the conjunctiva, cornea,  anterior chamber,  iris/pupil,  and lens.   The lens will 
also be evaluated  following dilation  for the cataract  assessment ; 
• Visual  Field  Examinations :  Visual  field  examinations (including historical tests  used  
for screening)  will be performed  using Humphrey automated  perimetry.   Acceptable test  
methods are the Humphrey 24-2 full -threshold or Swedish  Interactive  Threshold 
Algorithm (SITA) Standard tests.   The same test  methodology will be used  for all  study-
related  examinations  for a given subject ; 
• Dilated  fundus  exam :  Stereoscopic fundus assessments  should be conducted through a 
dilated  pupil.  The examination  will include evaluation  of the macula,  optic nerve,  
vitreous, and  retina.   The cup/disc (C/D) ratio  will also  be assessed  using the  Armaly  
Cup- Disc grading card . 
7.4. Other Assessments  
• Patient  Comfort of Eye Drops  Evaluation (questionnaire administered  by designated  
site personnel) (Part  2 only):  Subjects  are asked  to rate the overall comfort  of the eye 
drops.  
7.5. Methods  of Data  Collection  
This protocol will use electronic  case report  forms  (eCRFs)  with  remote  data capture through 
a qualified  third -party  vendor (iMednet) .  Data entered  into the eC RF will correspond to, and  
be supported by,  source documentation maintained  at the sites  (See Section  10.4.1, for 
i
nvestigator responsibilities  regarding source doc umentation  requirements).  The data will be 
entered  on the eCRFs  by appropriately trained  personnel in  a timely  manner  and on an  
ongoing basis.  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 34 2021.01.30  IWRS  will be used  to manage study treatment  inventory.  In  Part 2 only, IWRS  will also  
stratify  and randomize sub jects and assign  study treatment  kit numbers.  
A qualified  third -party  laboratory will be used  for the analysis  of blood and  urine samples.   
Laboratory results  will be provided to  the sites  by the vendor.  For statistical analysis  
purposes, laboratory  data  will be transferred  to Whitecap  Biosciences  (or designee)  at the end  
of each  part of the study; detailed  laboratory data will not be captured  in EDC . 
8. Study  Conduct  
This section  provides a high- level  summary  of when  during the study the procedures  are to  
be performed.   Detailed  information  on the examination  procedures, equipment, and  
techniques is  presented  in Attachment  12.2.  Th e  procedures should be performed  in the order 
as listed  on the Schedule of Visits  and Procedures  (see Table s 1, 2 and  3).  Th e  order of  the 
following procedures (Medical and  ophthalmic histories, Prior medications/t reatments , 
concomitant medications/t reatments ) can  be completed  at any time  during the study visit.   
For a glossary of terms  and abbreviations, see  Table  7; for a glossary of  subject  status  
definitions and  other definitions, see Table  8.  For a list of other study supplies besides  t he IP,  
see Attachment 12.3. 
This study consists of the following scheduled  visits:  
• P art  1 (4 visits) :  Screening  (Days  -50 to  -4); Baseline  (Day  -1); Days  1, 2/Exit; 
• Part 2 (5 visits) :  Screening  (Days  -50 to  -4); Baseline  (Day  -1); Days  1, 4, 14/ Exit; 
designated  site personnel will phone the subject  on the evenings before  Day s 4 and  
14/Exit to  remind  subjects  of dosing requirements  (See Section  8.4.2 for details) . 
S
everal  visits  (Part  1:  Baseline [Day  -1], Day  1; Part  2:  Baseline [Day  -1], Day 4, Day  
14/Exit) will consist of an  8-hour diurnal assessment.  
The following subsections provide details  on the conduct of the study and  list of procedures 
for each  scheduled  visit.  Listed  ocular  procedures  should be performed  on both eyes.   The 
procedures are listed  in the order in  which  they  should be performed  (unless otherwise 
specified.  
The Screening  visit will occur  between  4 and 50 days prior to  Baseline (Day  -1).  Final  
subject  qualification  for the study will be determined  at Baseline (Day  -1).  S ubjects  who  
qualify for the study will be considered  eligible  for study treatment  administration  and be 
assigned  to one of the cohorts in  a sequential  manner  (Part  1) or  randomly assigned  to one of 
the treatment  groups (Part  2). 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 35 2021.01.30  To minimize  diurnal variation  across  study visits,  particularly  for IOP,  the time  of 
examinations for each  subject ’s post- screening  study- related  activities  and examinations 
should remain  consi stent  over the course of the study.   IOP  measurements  should be 
performed  at approximately the same time  each  day based  on the time  of day  established  at 
the corresponding Baseline visit.   Hour 0 should occur  between  0700 and 0900 hours.  At the 
Baseline visit,  IOP measurements  should occur  2, 4 and  8 hours from  the time  of the Hour 0 
IOP evaluation.  At post- Baseline visits,  IOP measurements  should be obtained as  close as 
possible to  the same time  of day  as the corresponding timepoint at  Baseline. 
Evaluati ons should be performed  in the order  listed  in the Schedule of Visits  and Procedures  
(see Tables  1, 2 and  3).  Evaluations should be performed  by t he same evaluator  throughout 
the study whenever possible.  If it is  not possible to  use the same evaluator  to follow the 
subject,  then  evaluations should overlap  (ie, examine the subject  together and  discuss 
findings) for at  least  one visit.  
If a female becomes  pr egnant during the study, the investigator will notify Whitecap  
Biosciences  immediately  after  the pregnancy  is confirmed  and the subject will stop taking 
study treatment.   The subject  will be discontinued from  the study after  appropria te safety  
follow-up. See Section  6.4.3 for Procedures  for Pregnancy  Follow-up and  Reporting. 
8.1. Informed  Consent   
The study will be discussed  with  potential subjects.   Those who  are interested  must give 
written  informed  consent prior to  being subjected  to any study- related  procedures.  Written  
documentation will be obtained in  accordance with  relevant  country requirements  (ie, Written  
Authorization for Use  and Release of Health  and Research  Study Information  and local  
privacy  requirements,  where applicable.   See Section  10.1.3 for details  on the Informed  
Consent process.  
After  obtaining consent and authorization, potential subjects  will undergo a series  of 
preliminary  screening  procedures to  assess qualification  for the study.  At Screening,  each 
subject  will be assigned  a subject  number. 
8.2. Subject  Screening  Visit  /Screening  Period  (Days – 50 to –4) 
Subjects  who  provide informed consent will be assigned  a subject  identification  number that  
will be used  on all  study documents.  For each  subject,  the start  of the study is  defined  as the 
time the informe d consent  is signed.  Study- related  procedures and  data collection  for study 
purposes may  commence  only after  the informed  consent has  been  obtained.   All subjects  
(Part  1 and  Part 2) will undergo screening  that includes procedures  for initial qualificatio n at 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 36 2021.01.30  the Screening  visit followed by a Screening  period (washout/waiting  period, see Section  6.2) 
for those who  meet  required  Screening  visit eligibility  criteria  (see Sections 4.1 and  4.2 for 
inclusion/exclusion criteria).   For subjects  who  screen  fail, the reason  for screen  failure,  as 
well as demographic and  AE data will be collected  and reported  on the appropriate e CRF.  
Once informed  consent has  been  provided, the following procedures should be performed  in 
the order below:   
• Informed  consent and  authorization; 
• Query  to screen  for any  recent  event  that could jeopardize the subject’s  safety  prior to  
further screening ; 
• Subject  comfort  of eye drops evaluation  (for IOP-lowering agent(s)  subject  is taking at  
Screening)  (Part  2 only); 
• Medical  and ophthalmic histories  (including demographic data) ; 
• Prior medications  and treatments  (current  as well  as those that  have been  stopped within  
3 months prior to  the Screening  visit); 
• Physical  exam  (including height and  weight); 
• Respiratory  rate and temperature (seated) ; 
• Postural (supine/standing) blood pressure  and heart  rate; 
• Clinical labor atory  evaluation  (non-fasting), including CBC with  differential,  blood 
chemistries  and urinalysis.  Note:   The Screening  labs will be used  to determine  subject  
eligibility.   If repeat  testing  is required, a non- fasting  sample  should be drawn  at least  3 
days prior to  the scheduled  Baseline visit to  ensure results  are available for review  prior 
to randomization; 
• M acroscopic (gross) hyperemia evaluation ; 
• Visual  acuity  (V A):   Manifest  refraction  required  to obtain a correction  for VA evaluation ; 
• Slit-Lamp  Biomicroscopy;  
• IOP (GAT) ; 
• Visual  field:  May  be performed  up to  12 months prior to  or at  Screening  using the 
protocol- required  testing  method.  For subjects  requiring  pupil dilation,  the visual field  
should be performed  after  the IOP  measurement  or the next day.   The same  test 
methodology should be used  throughout the stu dy for a given subject; 
• Fundus exam  (including cup/disc ratio,  post-pupil dilation) ; 
• Begin  washout of all  IOP-lowering medication  (see Section  6.2); 
• Enter  subject  as "in  Screening” in  eDC ; 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 37 2021.01.30  • Preliminary  determination  of eligibility . 
Washout Period  (Days –50 to  –4) 
Eligible  subject  who  are being treated  with  IOP-lowering medication(s)  in either  eye will 
enter  the Screening  Period  and begin washout of these medication(s)  following the Screening  
visit.   Details  of the washout requirements  and options to  minimize  the absence of treatment  
during washout can  be found in  Section  6.2 and  Table  5.  Th e  Baseline visit will occur  
following the completion  of the washout period. 
Waiting  Period  (Days –4 to  –1) 
There is  a minimum of 3 days waiting  between  the Screening  and Baseline visits  for all  
subjects .  Additionally,  for subjects  who  have taken  IOP-lowering medications  prior to /at the 
screening  visit,  then  they  must also  adhere to  the appropriate washout period  (See Table  5). 
8.3. Subject  Enrollment  – Baseline  Visit  (Day  -1) 
A subject  is considered  to be enrolled  in the study when  s/he has  completed  all screening  and 
qualification  procedures and meets  all eligibility  criteria  at the Baseline (Day  -1) visit based  
on the inclusion/exclusion criteria  (see Section  4.1 and  4.2) and  confirmed  eligibility  on the 
morning of Day  1 (Part  1) AND has  been  randomized  at Day  1 (Part  2). 
Baseline  - Hour 0: 
• Adverse event  (AE) query 
• Medical  and ophthalmic histories  (including demographic data)  
• Prior medications  and treatments  (between  Screening  and Baseline) 
• Concomitant medications  and treatments  
• Respiratory  rate and temperature (seated)  
• Postural (supine) blood pressure  and heart  rate  
• 12 lead -ECG  
• Urine  Pregnancy  Test - Results  of pregnancy  tests (required  for female subjects  of 
childbearing potential only) must be obtained prior to  treatment  and must be  negative for 
the subject  to be eligible    
• Macroscopic (gross) hyperemia evaluation  
• Pupil Size using near  card  (Part  2 only) 
• Vi sual  acuity  (V A):   Manifest  refraction  required  to obtain a correction  for VA evaluation   
• Contrast Sensitivity  (Part  2 only) 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 38 2021.01.30  • Slit-Lamp  Biomicroscopy 
• IOP (GAT)  
• Visual  field:  The 2nd VF examination  can be performed  at any time  prior to  pupil 
dilation    
• Confirm  2 reliable  fields  are available and  meet  entry  criteria.    
Baseline  - Hours  2, 4, 8 
• Macroscopic (gross) hyperemia evaluation  
• Pupil Size using near  card  (Part  2, Hour 2 only) 
• S lit- Lamp  Biomicroscopy 
• IOP (GAT)  
8.3.1. Procedures  Prior to  Randomization (Part  2 only) 
At the end  of the Screening  period, subjects  will be assessed  at the Baseline  (Day  -1) visit for 
eligibility.   Qualified  subjects  will return  the morning of Day  1 where  eligibility  will be 
confirmed.  Eligible  subjects  may  then  be randomized. (Note:   Subjects  who  do not meet  
eligibility  criteria  at Baseline  (Day  -1) or confirmation  of eligibility  on Day  1 before  dosing 
occurs  will be exited  from  the study as  screen  failures).   
Only  eligible  subjects  will be randomized. 
8.3.2. Randomization Procedures  (Part  2 only) 
Prior to  randomization of a subject,  the site  will be required  to enter  certain  data into  eDC.  
For IOP,  each  of the  Baseline  (Day  -1) IOP measurements  (either  2 or 3 per  eye per  hour) 
will need  to be entered  into IWRS , within  eDC.  These measurements  will be used  to confirm  
that the subject  meets  IOP inclusion criterion  numbers 3 e and  f (see  Section  4.1).   F or 
confirmed  qualified  IOP, IWRS  will assign  a stratification  code based  on the  IOP value(s) 
entered , randomize the subject  and assign  a study kit number.  The kit number corresponds to  
the assigned  study treatment  for the subject.   See  Study Randomization Procedures  in the 
IWRS  section  of the Study Reference Manual  for detailed  instructions on randomiz ation  
procedures. 
8.4. Study  Visits  and Procedures  for Enrolled  Subjects   
8.4.1. Part  1 - Study  Visits  and Procedures  for Enrolled  Subjects   
See Table  2 fo r the Schedule of Visits  and Procedures  in Part 1.  Visits  in Part 1 should occur  
on the designated  day.   No windows will be allowed.    
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 39 2021.01.30  Part  1 - Day  1 (Hour  0, pre -1st dose) 
• Adverse event  (AE) query 
• Concomitant medications  and treatments  
• Postural (supine/standing) blood pressure  and heart  rate 
• Macroscopic (gross) hyperemia evaluation  
• Visual  acuity  (V A):   Manifest  refraction  performed  at Baseline (Day  -1) should  be used  
for visual acuity  evaluation.   Manifest  refraction(s) may  be repeated,  if in the opinion of 
the investigator, it is  necessary .   
• Slit-lamp  biomicroscopy 
• IOP (GAT)  
• Confirm  Inclusion/Exclusion Criteria  are still met  
• Study medication  assignment 
• Enter  Treatment  Assignment form  in eDC   
• Site to administer  study medication  
Part  1 - Day  1 (30 minutes  post- dose)  
• Macroscopic (gross) hyperemia evaluation  
• Slit-lamp  biomicroscopy 
• IOP (GAT)  
Part  1 - Day  1 (Hour  2) 
• Postural (supine/standing) blood pressure  and heart  rate 
• Macroscopic (gross) hyperemia evaluation  
• Slit-lamp  biomicroscopy 
• IOP (GAT)  
Part  1 - Day  1 (Hours  4 and 8) 
• Macroscopic (gross) hyperemia evaluation  
• Slit-lamp  biomicroscopy 
• IO P  (GAT)  
Part  1 - Day  2 (Hour  0) 
• Adverse event  (AE) query 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 40 2021.01.30  • Concomitant medications  and treatments  
• Postural (supine/standing) blood pressure  and heart  rate 
• Urine  pregnancy  test (females  of child -bearing potential only) 
• Macroscopic (gross) hyperemia evaluation  
• Visual  acuity  (V A):   Manifest  refraction  performed  at Baseline  (Day  -1) should be used  
for visual acuity  evaluation.   Manifest  refraction(s) may  be repeated,  if in the opinion of 
the investigator, it is  necessary.   
• Slit-lamp  biomicroscopy 
• IOP (GAT)  
• Fundus exam  (including cup/disc ratio,  post-pupil dilation)  
Following the completion  of the Day  2/Exit examination, the subject  will exit  the study. 
8.4.2. Part  2 - Study  Visits  and Procedures  for Enrolled  Subjects   
Visit windows will be applied  in Part 2 only.  Visit  windows of ±1  day will be allowed.   In 
Part 2, for each subject , the schedule of  all post-baseline visits  should be determined  using 
the date of the Baseline visit.  
Part  2 - Day  1 (Hour  0, Pre -1st Dose ) 
• Adverse event  (AE) query 
• Concomitant medications  and treatments  
• Postural (supine/standing) blood pressure  and heart  rate 
• M acroscopic (gross) hyperemia evaluation  
• Visual  acuity  (V A):   Manifest  refraction  performed  at Baseline (Day  -1) should be used  
for visual acuity  evaluation.   Manifest  refraction(s) may  be repeated,  if in the opinion of 
the investigator, it is  necessary.   
• Slit-lamp  biomicroscopy 
• IOP (GAT)  
• Confirm  Inclusion/Exclusion Criteria  still met  
• Randomize subject  / obtain kit assignment / dispense a single bottle  of study medication  
for first  dose 
• Site to administer  1st dose of study medication  to each eye 
Part  2 - Day  1 (30 minutes  post- dose)  (±5 minutes)  
• Subject  Comfort  of Eye  Drop  Evaluation 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 41 2021.01.30  • Macroscopic (gross) hyperemia evaluation  
• Slit-lamp  biomicroscopy 
• IOP (GAT)  
Part  2 - Day  1 (Hour  2) (±10 minutes)  
• Postural (supine/standing) blood pressure  and heart  rate 
• Macroscopic (gross) hyperemia evaluation  
• Slit-lamp  biomicroscopy 
• IOP (GAT)  
• Review  instillation  technique and  give study medication  to the subject  to take home  
Part  2 – Evening  before  Day  4 and Day  14/ Exit  
• On the evenings before  Day 4 and  Day  14/Exit, designated  site personnel will remind  
subjects  to dose their  evening dose approximately 12 hours prior to  their  next morning 
Hour 0 timepoint and  to not dose the following morning (study medications  will be 
administered  by designated  site personnel at  the end of the Hour 0 timepoint) . 
Part  2 - Days 4 and 14/Exit  (Hour  0) (±10 minutes)  
• Adverse event  (AE) query 
• Concomitant medications  and treatments  
• Postural (supine/standing) blood pressure  and heart  rate 
• Macrosco pic (gross) hyperemia evaluation  
• Pupil Size using near  card  (Day  14/Exit only) 
• Vi sual  acuity  (V A):   Manifest  refraction  performed  at Baseline (Day  -1) should be used  
for visual acuity  evaluation.   Manifest  refraction(s) may  be repeated,  if in the opinion of 
the investigator, it is  necessary.   
• Contrast sensitivity  (Day  14/Exit only) 
• S lit- lamp  biomicroscopy 
• IOP (GAT)  
• Site to administer  study medication  at end of Hour  0 examination  
• Site to collect  study medication  following final  dose (Day  14/Exit only) 
Part  2 - Day  14/Exit  only,  once final  dose has been  administered  
• Clinical laboratory evaluation  (non-fasting)   
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 42 2021.01.30  • Urine  pregnancy  test (females  of child -bearing potential only) 
Part  2 - Day  14/Exit  only (30  minutes  post- dose)  (±5 minutes ) 
• Subje ct Comfort  of Eye  Drops Evaluation (administered  by designated  site personnel) 
Part  2 - Days 4 and 14/Exit  (Hour  2) (±10 minutes)  
• Postural (supine/standing) blood pressure  and heart  rate 
• ECG  (Day  14/Exit only) 
• Macroscopic (gross) hyperemia evaluation  
• Pupil Size using near  card  (Day  14/Exit only) 
• S lit- lamp  biomicroscopy 
• IOP (GAT)  
• Visual  Field  (may  occur  at any time  from  Hour 2 prior to  pupil dilation)  (Day  14/Exit 
only) 
Part  2 - Days 4 and 14/Exit  (Hours  4 and 8) ( ±10 minutes) 
• Macroscopic (gross)  hyperemia evaluation  
• Slit-lamp  biomicroscopy 
• IOP (GAT)  
• Fundus exam  (including cup/disc ratio,  post-pupil dilation)  (Day 14/Exit, Hour 8 only) 
Following the completion  of the Day  14/Exit examination, the subject  will exit  the study. 
8.5. Unscheduled Visits  and Associated  Procedures  
Additional examinations may  be conducted as  necessary  to ensure the safety  and well -being 
of subjects  during the study period.  eCRFs  should be completed  for each  unscheduled visit.   
For all  parameters  not measured,  indicate  “Not  Done”.  
Subjects  may  experience adverse events  that necessitate their  returning for unscheduled 
visits.   The adverse event  and all required  information should be recorded  on the appropriate 
eCRF  and the subject ’s record  should include all relevant  information.   
8.6. Instructions for Subjects   
The principal investigator  or designated  study personnel will instruct the subject  on proper 
dosing techniques prior to  dispensing the study treatment  to the subject .  The sites will 
contact  subjects  routinely to  remind  them  to administer  their  study treatment  as instructed.  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 43 2021.01.30  After  each  subject has  signed the informed  consent, s/he will be instructed  as follows:  
• To provide a list of all  medications  (prescription, non- prescripti on, vitamins,  herbal  
supplements), taken  within  the 3 months prior to  Screening  and those that  will be 
continued during the study period, including the dose and  the reason  for taking the 
medication  and a list of any non- medicinal  treatments ; 
• At Screening,  subjects  whose IOP  is currently  being treated  with  IOP-lowering 
medication(s)  will be instructed  by the site  to stop taking the IOP -lowering meds  
(ie, begin the washout period) following the Screening visit.   The washout period will be 
a minimum of 4 days to  6 weeks  depending on the schedule in  Table  5.  Subjects  may be 
instructed  to return  for a visit during the washout period so  that the investigator may  
assess their  IOP; 
• To return  to the study site,  at approximately the same  time  of day  established  at Baseline 
(Day  -1); 
• To remain  at the site  to complete  the remainder  of the day’s study- related  procedures  as 
explained  to them  by the study site  personnel; 
• To refrain  from  swimming  and smoking, being exposed to  smoke or other exposure that  
might cause eye irritation  during the study; 
• To refrain  from  drinking more  than  ½ cup  of liquid within  1 hour prior to  IOP 
measurement ; 
• To avoid discussing side effects  (if any  experienced) with  other subjects  in the trial; 
• If spectacles  are worn  for vision correction,  subjects should remember  to bring the 
spectacles  each time  they  visit the doctor’s office ; 
• Females  of childbearing potential should be reminded  that they  are to  maintain  the agreed  
to contraception  method throughout the study and  notify the site  in the event  of a 
pregnancy, up to  30 days after exiting  from  the study (see Section  6.4.3); 
• Subje cts should also  be reminded  to contact  the study site  if they  are experiencing  any 
difficulties  during their  study participation.  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 44 2021.01.30  In Part 2 only, s ubjects  will also  be instructed  as follows: 
• On proper dosing of ocular  medications  and to dose study medicati on as  directed:   
administer  one drop in  each  eye each evening (between  1900 and  2100 hours) starting  the 
evening of Day  1 and  each  morning (between  0700 and  0900 hours) through the evening 
of Day  13. The final  dose of study medication  on the morning of Day  14/Exit will be 
administered  by site  personnel after  the Hour 0 examination.   Subjects  will be reminded  
to take their  study medications  approximately 12 hours before their  Hour 0 appointments 
the evening prior to  a post- baseline study visit and  to not dose in  the morning of Days  4 
and 14.  If desired,  subjects will also  be given the option for periodic (eg,  daily)  
reminders  from  the Site  to take their  study medications  each  morning and  evening; 
• On proper storage conditions for study medications.   The study medications  should be 
kept in  their  unit carton  (box).  Do  not show the bottles  to other subjects  or study staff  
(except  the individual who  dispenses the study medication  to the subject ).  The study 
medications  may  be stored  at room temperature during the study period (between  59°F 
and 77°F) ; 
• To bring all  used  and unused study medication  to all visits  and to remind  subjects  that all 
study medications  will be collected  by the site  at the Day  14/Exit visit. 
8.7. Safety Monitoring  
Investigators are responsible for identifying, monitoring and  reporting  adverse events  that 
occur  throughout the study ( from  subject  signing of informed  consent through study exit).   
Any adverse event  that is marked  ‘ongoing’ at  the exit visit should be followed -up as  
appropriate until the event  is resolved  or deemed  chronic or stable  by the  Study Investigator.  
8.7.1. Procedures  for Collecting  and Reporting  Adverse  Events  
Adverse events  will be assessed,  documented, and recorded  in the e CRF  throughout the study 
(ie, after  informed  consent has  been  obtained).  At each  visit,  the investigator will begin by 
querying for adverse events by asking each  subject a general,  non- directed  question such  as 
“How  have you been  feeling  since the last  visit?”   Directed  questioning and  examination  will 
then be done as  appropriate.  All reported  adverse  events  will be documented on the 
appropriate e CRF.  
If, after  obtaining the subject’s  informed  consent but prior to  administration  of study 
product/treatment,  a medical  condition is  identified  via a study entry  protocol assessment  or 
procedure (eg,  screening  ECG  test)  which, based  on the Investigator’s judgment (and  in 
consultation with  the subject),  is determined  to be a pre -existing  condition (ie,  a condition 
existing  prior to  the time  of the subject’s  informed  consent), it should be documented on the 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 45 2021.01.30  appropriate e CRF.   Otherwise,  the condition should be reported  as a pre -treatment adverse 
event.   
All adverse events  that are drug- related  and unexpected  (not listed  as treatment -related  in the 
current  Investigator's Brochure)  must be reported  to the governing Institutional Review  
Board/Independent Ethics  Committee  (IRB/IEC) as  required  by the IRB/IEC,  local  
regulations, and  the governing health  authorities.    
8.7.2. Severity  
A clinical  determination  will be made of the intensity  of an  AE.  The severity  assessment  for 
an AE must be completed  using the following definitions as  guidelines: 
Mild  Awareness  of signs or symptoms,  but easily  tolerated  
Moderate  Discomfort  enough to  cause interference  with  usual activity  
Severe  Incapacitating  with  inability  to work  or do usual activity  
Not Applicable In some cases,  an AE may  be an  ‘all or nothing’ finding that  cannot be 
graded  (eg, death) 
8.7.3. Relationship  to Study  Drug  or Study  Procedure  
A determination  will be made of the relationship  (if any) between  an AE and the study drug 
or study procedure, as  applicable.   A causal  relationship  is present  if a determination  is made 
that there is  a reasonable possibility  that the AE may  have been  caused  by the study drug or 
study procedure. 
8.7.4. P rocedures  for Reporting  a Serious  Adverse Event  
Any serious adverse event  must be immediately  reported  but no later  than  24 hours after  
learning  of the serious adverse event.  The first report  should be submitted  even  if the 
available information  is minimal.  All subjects  with  a serious adverse event  must be followed 
up and  the outcomes reported.   The investigator must supply Whitecap  Biosciences  and the 
IRB/IEC  with  any additional requested  information  (eg, autopsy reports, discharge 
summaries).    
In the event  of a serious adverse event,  the investigator must: 
1. Notify  Whitecap  Biosciences  (or designee)  immediately  by email  using the Serious 
Adverse Event  Form;  phone numbers and  relevant  Whitecap  Biosciences  (or designee)  
personnel contacts  are on the front  page of  this protocol. 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 46 2021.01.30  2. Obtain  and maintain  in his/her files  all pertinent medical  records,  informa tion, and  
medical  judgments from  colleagues  who  assisted  in the treatment  and follow-up of the 
subject.  
3. Provide Whitecap  Biosciences  (or designee) with  a complete,  written  description  of the 
adverse event(s)  on the Serious Adverse Event  Form  describing the event  
chronologically, including any  treatment  given (eg, medications  administered,  other 
treatments  given) for the adverse event(s).   Summarize relevant  clinical  information  
about the event:   signs, symptoms, diagnosis, clinical  course and relevant  clinical  
laboratory tests,  etc.  Include any  additional or alternative  explanation(s) for  the 
causality  which  includes a statement  as to whether  the event  was or was not related  to 
the use of the investigational drug. 
4. Provide follow-up SAE  reports to  Whitecap  Biosciences  (or designee)  as more  
information  becomes  available  
5. Promptly  inform  the governing IRB/IEC  of the serious adverse event  as required  by the 
IRB/IEC,  local  regulations, and  the governing health  authorities.  
See Study Reference Manual for additional details.  
8.8. Procedures  for Stopping  Study  Treatment   
Part 1- There are no specific  procedures  for stopping treatment.  
Part 2 - When  the study treatment  is stopped for an individual subject  prior to  the protocol 
defined  duration for study treatment  administra tion, the Day  14/Exit (Hour 0) procedures,  at 
a minimum should be performed.   The reason  that the study treatment  is stopped should be 
documented on the appropriate e CRF.  
8.9. Early  Study  Exit Procedures  
8.9.1. Subject  Discontinuation/Withdrawal from  the Study  
• A subject  may  withdraw from  the study at  any time  at his/her own  request,  or may  be 
withdrawn  at any time  at the discretion  of the investigator for safety,  behavioral, 
compliance,  or administrative  reasons ;   
• If the subject  withdraws  consent for disclosure of future  information, the sponsor may  
retain  and continue to  use any  data collected  before  such  a withdrawal  of consent; 
• If a subject  withdraws  from  the study, he/she may  request  destruction  of any  samples  
taken  and not tested,  and the investigator must document this  in the site  study  records ; 
• A subject  who  is enrolled,  but who  had significant deviation from  protocol- specified  
inclusion/exclusion criteria,  may  be discontinued from  participation  in the study; 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 47 2021.01.30  • If a female becomes  pregnant during the study, the investigator will notify Whitecap  
Biosciences  immediately  after  the pregnancy  is confirmed  and the subject will stop taking 
study treatment.   The subject  will be discontinued from  the study after  appropria te safety  
follow-up. See Section  6.4.3 for Procedures  for Pregnancy  Follow-up and  Reporting; 
• Subjects  who  are exited  before  completing  the study may  be replaced.  
See Schedule of Visits  and Procedures  for specific  data to  be collected  at the time  of study 
discontinuation and  follow-up and  for any  further evaluations that  need  to be completed.   If a 
subject  is discontinued prior to  completing  the study, the procedures outlined  for the Day  
2/Exit visit (for Part  1) or the Day  14/Exit visit (Hour 0 timepoint at  a minimum)  for Part  2 
should be performed  at the last  visit attended.  
When  a subject exits  before completing  the study, the reason  for the early  exit will be clear ly 
documented on the appropriate e CRF.  
If the subject  exits  before  completing  the study, any  serious adverse events  or treatment -
related  non-serious adverse events  occurring within  14 days after  the last  dose of study 
treatment  should be reported  to the Si te.   
8.9.2. L ost to  Follow Up  
A participant  will be considered  lost to  follow-up if  he or she repeatedly  fails  to return  for 
scheduled  visits  and is unable to  be contacted  by the study site.   
The following actions  must be taken  if a participant fails  to return  to the clinic  for a required  
study visit:  
• The site must attempt to  contact  the participant and  reschedule the missed  visit as  soon as  
possible and  counsel the participant  on the importance of maintaining  the assigned visit 
schedule and  ascertain  whether  or not the participant  wishes  to and/or should continue in  
the study; 
• Before  a participant  is deemed  lost to  follow up, the investigator or designee must make 
every  effort  to regain  contact  with  the participant  (where possible, 3 telephone calls  and, 
if neces sary, a certified  letter  to the participant’s  last known mailing  address  or local  
equivalent methods). These  contact  attempts  should be documented in  the participant’s  
medical  record ; 
• Should the participant  continue to  be unreachable,  he/she will be considered to  be lost to  
follow up and  exited  from  the study;  
• When  a subject is  lost to  follow-up, the reason  for the early  exit will be clearly  
documented on the appropriate e CRF.  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 48 2021.01.30  8.10. Procedur es for Unmasking of Study  Medication  
When  necessary  for the safety  and proper treatment of the subject,  the investigator can  
unmask the subject’s  treatment assignment to  determine  which  treatment has  been  assigned  
and institute  appropriate follow-up care.   When  possible, Whitecap  Biosciences  (or designee)  
should be notified  prior to  unmasking study medication.   The investigator should inform  
Whitecap  Biosciences  (or designee)  of the unmasking if  there is  no notification  prior to  the 
unmasking.  
The treatmen t assignment  for the subject  can be determined  by designated  site personnel 
through the IWRS  via password protected  access.   The reason  for breaking  the code must be 
recorded  in the subject’s  source documents.  See Study Reference Manual  for additional 
details. 
9. Statistical Procedures  
One database lock  will occur  when  all subjects  (both Part  1 and  Part 2) have either  completed  
the study or discontinued from  the study prematurely,  and all data queries  have been  
resolved.  Randomization  release will occur  following the database lock.   A detailed  
statistical analysis  plan  (SAP)  will be approved prior to  database lock.  
9.1. Analysis Population(s)  
Each  population will be analyzed  based  on the treatment received.  
Part 1:  The Safety  population consisting of all  treated  subjects  will be used  for all analyses.  
Part 2: The following populations will be used  for analysis:   
• The Safety  population will  consist of all  treated  subjects.  All safety  analyses  will be 
performed  using the safety  population; 
• The Modified Intent- to-treat (mITT) will consist of all  randomized  and treated  subjects  
who provide IOP  data at  baseline and  at least  one post- baseline IOP  assessment.   This 
population will be used  for analyses  of efficacy  data; 
• The Per-protocol (PP)  population is  a subset of the mITT  population and  will consist of 
subjects  who  did not have any  major  protocol violations deemed  to have potential impact  
on the primary  endpoint.  This population will be used  to confirm  the primary  efficacy  
analysis  and will be determined  prior to database lock. 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 49 2021.01.30  9.2. Sample  Size Calculation  
For each  cohort in  Part 1 of the study a sample  size of 6 patients  will provide 83% power to  
detect  a 3 mmHg  within -group change from  pre-dose assuming a standard  deviation of 2 and  
two-sided  alpha = 0.05, based  on a one- sample  t-test.  With  larger  standard  deviations ( ≥2.5) 
the power to  detect  this difference is  <66%. 
For Part  2, a sample  size of 24 has  > 90% power  to detect  a within -group mean  changes from  
baseline IOP  of 3 mm Hg,  assuming a SD  of 2.5 mm Hg.   Also,  power calculations  were 
performed  for the comparison of each  dose of AGN–227535 versus Timolol.   These 
calculations  consider treatment  differences  (AGN–227535 minus Timolol)  mean  changes  
from  baseline in  study eye IOP  in the mITT  population at  Day  14/Exit.  
The power to  detect  treatment  group differences  from  -1 to  -4 mm Hg  with  common standard  
deviations (SDs) ranging from  2.5 to  3.5, based  on a two -sample  t-test are shown in  Table  6. 
Table  6 Power  Calculations for  Study  Part  2 Tests  of Treatment  Differences  
(AGN -227535 N = 24; Timolol N = 12; alpha = 0.05)  
Treatment Group 
Difference  Common  
SD Power  
(%) 
-4 2.5 99 
3 96 
3.5 88 
-3 2.5 91 
3 78 
3.5 65 
-2 2.5 59 
3 45  
3.5 35 
-1 ≥2.0 <20 
Additional sample  size calculations  were performed  for tests  of non- inferiority  of either  dose 
of AGN -227535 to  Timolol.   These calculations  considered  a non- inferiority  margin  of 1.5 
mm Hg  and one- sided  α = 0.025.   With  a treatment group difference of -1 mm Hg,  the power 
ranged  from  50% for a common SD  of 3.5 to  78% for a common SD  of 2.5. 
The calculation  was based  on the non- inferiority  tests  for the difference between  two means  
using t- test as implemented  in the commercial  software  PASS  version 16.0.3 (2018). 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 50 2021.01.30  9.3. Methods  of Analyses  
In general,  data will be summarized  with  descriptive statistics  which  will include sample  
size, mean,  standard  deviation, median,  minimum and maximum for continuous variables  
and frequency  and percentage for c ategorical  variables .   
Part 1: All safety  and IOP-lowering effects  tabulations will provide descriptive statistics  by 
cohort. 
Part 2: For continuous variables,  treatment  groups will be compared  using analysis  of 
variance covariance techniques  or two -sample  t-tests.   Nominal variables  will be 
analyzed  using Pearson's chi-square test  or Fisher's exact  test.   
Analyses  performed  for the mITT  population will use the method of last  observation carried  
forward  (LOCF) to  impute  missing  values.   No imputation  for missing  data will be 
performed  for the PP  or safety  populations.   
As this is an exploratory trial, all treatment  comparisons will be made at  the two -sided  α = 
0.05 level  without adjustment for multiple  comparisons.  
9.3.1 Efficacy  (Part  2) 
9.3.1.1. Primary  Efficacy  Endpoint(s)  
The primary  response measure is  IOP.   Two consecutive measurements  of IOP  will be taken  
for each  eye,  with  the right  eye measured  first.   If the first  two measurements  of either  eye 
differ  by more than  two mm Hg,  a third  measurement  will be taken  for the  eye.   Depending 
on the number of measurements  required  and obtained, the IOP  for a given eye will be 
represented  by either  the average or the median  of the readings.  Details  will be provided in  
the SAP .  
The change from  baseline for each  eye at  each post- baseline assessment  is calculated  as the 
IOP at that assessment  minus the IOP  at the corresponding hour at  baseline.   Efficacy  will be 
evaluated  in the study eye.  The study eye is  the eye that  meets  the inclusion/exclusion 
criteria.   If both eyes  meet  the criteria,  the study eye will be the eye with the worse  (highest) 
IOP at Day  -1 Hour 0.  If both eyes  have the same IOP value at  this timepoint,  the right eye 
will be the study eye.  
The primary  efficacy  endpoints are the Day  14/Exit  mean  IOP changes  from  Baseline (Day  -
1) at each  time -matched  hour (0,  2, 4, 8).  The primary  hypothesis is  that AGN-227535 
ophthalmic solution effectively  lowers  IOP.   The primary  efficacy  analysis  is the within -
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 51 2021.01.30  group mean  change from  baseline at  Hour 2, the  time  of peak  efficacy  of timolol.   This study 
will also  asses s if AGN -227535 is  non- inferior to  Timolol ophthalmic solution 0.5% with  
respect  to change from  baseline (follow -up minus baseline)  in study eye IOP at each  time -
matched  hour evaluated  (hours 0, 2 4, and  8) at  Day  14/Exit in  the mITT  population.  The 
analyses  will be performed  via analysis  of covariance (AN COV A)  which  will have treatment  
as the main  effect  and the Baseline hour- matched  IOP as the covariate in  the model.  
Pairwise  treatment  group comparisons will be performed  for each  individual dose of AGN-
227535 versus timolol ophthalmic solution 0.5%. A 2- sided  95% confidence interval  (CI) for 
the treatment  difference (AGN-227535 Ophthalmic Solution minus Timolol  ophthalmic 
solution 0.5%) will be constructed  based  on this  ANOV A  model for each  AGN-227535 dose.   
AGN-227535 ophthalmic solution will be considered  to be non-inferior to  Timolol 
ophthalmic solution 0.5% if  the upper limit of the 95% CI  does not exceed  1.5 mmHg  at the 
majority  of timepoints  evaluated  (ie, 3/4) at the Day  14/Exit visit.   If AGN-227535 
ophthalmic solution is  determined  to be non- inferior to  Timolol ophthalmic solution 0.5%, a 
further attempt to  show superiority of AGN-227535 over Timolol will be made.    
Primary  efficacy  will be evaluated  in the mITT  population.  
9.3.1.2. Secondary  Efficacy  Endpoint(s)  
Mean  IOP at Day  14/Exit. 
Mean  IOP change from  baseline at  each  time -matched  hour via analysis  of variance 
(ANOVA)  which  will have treatment  and the Baseline IOP  stratum (IOP  ≤25 mm Hg  and > 
25 mm Hg  as the main  effects  in the model. 
9.3.2.  Safety Analyses 
All safety  analyses  will be performed  on the Safety  Population. 
The Medical  Dictionary  for Regulatory Activities  (MedDRA)  nomenclature will be used  to 
code adverse events.  A detailed  definition  of treatment emergent  adverse events (TEAEs)  will 
be provided in  the SAP . The number and  percent  of subjects  with  adverse event  reports  will 
be tabulated  for all  treatment  emergent  adverse events (TEAEs)  regardless  of causality,  
treatment -related  TEAEs , all serious TEAEs,  treatment -related  serious TEAEs , and  all 
adverse events  leading  to premature discontinuation of study treatment.   
For Part  2, analyses  of macroscopic hyperemia and  hyperemia as  evaluated  on 
biomicroscopy will include evaluation  of peak  severity  at each  post- baseline visit (Days  4 
and 14) and  across  all post- baseline time  points.  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 52 2021.01.30  Detailed  methods for analyses  of all  safety  variables  will be provided in  the SAP.  
9.4. Other Analyses  
The primary  analysis  (see Section  9.3.1.1) will be performed  fo r the PP  population. 
Additional planned analyses  include treatment  comparisons of:  
• Mean  diurnal IOP  (average of IOP  measurements  taken  throughout the day)  change from  
baseline.   The same methods as  described  in Section  9.3.1.1 will be used ;  
• IOP values  at each  scheduled  hour of Day  14/Exit .  Analyses  will be performed  using an 
ANC O VA  model with  treatment as  the main  effect  and baseline IOP  hour- matched  IOP as 
the covariate;  
• Mean  diurnal IOP  at Day  14/Exit. Analyses  will be performed  using a two -way ANCO VA  
model with  treatment  as the main  effect  and baseline mean  diurnal IOP as the covariate. 
Additional exploratory analyses  may  be described  in the SAP.   
9.5. Subgroup  Analyses  
For Part  2, descriptive statistics  for the primary  analyses  will be provided by Baseline IOP  
stratum.  Additional subgroup analyses  may  be specified  in the SAP .   
9.6. Interim  Analyses  
No interim statistical analysis is  planned. 
10. Supporting  Documentation  and Operational  Considerations  
10.1. Regulatory,  Ethical,  and Study  Oversight  Considerations  
10.1.1. Regulatory and Ethical  Considerations 
This study will be conducted in  accordance with  the protocol and  with  the following: 
• Consensus ethical  principles derived  from  international guidelines including the 
Declaration  of Helsinki and Council for International  Organizations of Medical  Sciences  
(CIOMS) International  Ethical  Guidelines; 
• Applicable ICH  Good Clinical  Practice (GCP)  Guidelines ; 
• Applicable laws  and regulations; 
• The protocol, protocol amendments, ICF,  Investigator Brochure, and  other relevant  
documents (eg,  advertisements)  must be submitted  to an IRB/IEC  by the investigator and  
reviewed  and approved by  the IRB/IEC  before  the study is  initiated ;  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 53 2021.01.30  • Any amendments  to the protocol will require  IRB/IEC  approval before  implementation  of 
changes  made to  the study design, except  for changes  necessary  to eliminate  an 
immediate  hazard  to study subjects ;  
• The investigator will be responsible for the following: 
o Providing written  summaries  of the status  of the study to  the IRB/IEC  annually or 
more  frequently  in accordance with  the requirements, policies,  and procedures  
established  by the IRB/IEC  
o Notifying the IRB/IEC  of SAEs  or other significant safety  findings as  required  by 
IRB/IEC  procedures 
o Providing oversight of the conduct of the study at the site  and adherence to  
requirements  of US 21 CFR,  ICH  guidelines, the IRB/IEC,  and all other applicable 
local  regulations. 
10.1.2. Financial Disclosure 
Investigators and  sub- investigators  will provide the sponsor with  sufficient,  accurate financial  
information  as requested  to allow  the sponsor to  submit complete  and accurate financial  
certification  or disclosure statements  to the appropriate regulatory authorities.  Investigators 
are responsible for providing inf ormation  on financial  interests  during the course of the study 
and for 1 year  after  completion  of the study. 
10.1.3. Informed  Consent  Process  
• Th e  investigator or his/her representative will explain  the nature of the  study to  the 
participant  or his/her legally  authorized  representative and  answer  all questions regarding 
the study;  
• Subjects  must be informed  that their  participation  is voluntary.  Subjects  or their  legally  
authorized  representative  will be required  to sign a statement  of informed  consent that  
meets  the requirements  of US 21 CFR 50, local  regulations, ICH  guidelines, Health  
Insurance Portability  and Accountability Act (HIPAA) requirements,  where  applicable,  
and the IRB/IEC  or study center ;  
• The medical  record /source document must include a statement  that written  informed  
consent was  obtained before the subject  was entered  in the study and  the date the written  
consent was  obtained.  The authorized  person  obtaining the informed  consent must also  
sign the ICF ; 
• If the ICF  is modified  during the subject’s  participation  in the study, it may  be required  
for the subject  to be re-consented;  
• A copy of the ICF(s) must be provided to  the subject or the subject’s  legally  authorized  
representative.   
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 54 2021.01.30  10.1.4. Data  Protection  
• Subjects  will be assigned  a unique identifier  by the  sponsor.  Any participant records  or 
datasets  that are transferred  to the sponsor wi ll contain  the identifier  only; participant  
names  or any  information  which  would make the participant  identifiable  will not be 
transferred ;  
• The subject  must be informed t hat his/her personal study- related  data will be used  by the 
sponsor in  accordance with  local  data protection law.   The level  of disclosure must also  
be explained  to the subject;  
• The subject  must be informed that  his/her medical  records  may  be examined  by Clinical 
Quality  Assurance auditors or other authorized  personnel appointed by the sponsor, by 
appropriate IRB/IEC  members,  and by inspectors from  regulatory authorities.  
10.1.5. Coordinating Investigator 
A signatory Coordinating Investigator will be designated  prior to  the writing  of the Clinical 
Study Report. 
10.2. Protection  of Human  Subjects  
10.2.1. Subject  Confidentiality  
A report  of the results  of this  study may  be published or sent  to the appropriate health  
authorities  in any country in  which  the study drug may  ultimately  be marketed,  but the 
subject’s  name will not be disclosed  in these documents.  The subject's name may  be 
disclosed  to Whitecap  Biosciences  or the  governing health  authorities  (eg, US FDA,  
Canadian  Committee  for Medicinal  Products for Human  Use [CHMP],  US Pharmaceutical  
and Medical  Devices  Agency,  Japan  PMDA)  if they  inspect  the study records.  Appropriate 
precautions will be taken  to maintain  confidentiality  of medical  records  and personal 
information. 
10.2.2. Subj ect Privacy  
Written  authorization and  other documentation in  accordance with  the country and  local  
privacy  requirements  (where  applicable)  is to be obtained from  each  subject prior to  
enrollment into  the study, and/or from  the subject's legally  authorized  representative in  
accordance with  the applicable privacy requirements (eg,  the Health  Insurance Portability  
and Accountability  Act Standards for Privacy  of Individually Identifiable  Health  Information  
(“HIPAA”).  
In accordance with  country- specific requirements,  additional purposes of this  study may  
include publishing of anonymized subject  data from  the study. 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 55 2021.01.30  10.2.3. Compliance  with  Informed  Consent  Regulations and Relevant  Country  
Regulations 
Following informed  consent regulations (eg,  US 21 CFR Part  50) Written  informed  consent 
is to be obtained from  each  subject  prior to  any study- related  activities  or procedures in  the 
study, and/or from  the subject's legally  authorized  representative.    
1. That the study involves research ; 
2. The objectives  of the study; 
3. The study procedures ; 
4. The expected  duration of the subject’s  participation  in the study; 
5. The approximate number of subjects  involved in  the study; 
6. The reasonably foreseeable risks  or inconveniences to  the subject ; 
7. The alternative  procedures or courses of treatments  that may  be available to  the subject,  
and their  important potential benefits  and risks ; 
8. The compensation and/or treatment  available to  the subject  in the event  of study- related  
injury; 
9. That the subject’s  participation  in the study is  volunt ary and that the subject may  refuse  to 
participate  or withdraw from  the study at  any time,  without penalty  or loss of benefits  to 
which  the subject  is otherwise entitled ; 
10. T hat  subject  will be informed in  a timely  manner  if information  becomes  available  that 
may be relevant  to the subject’s  willingness  to continue participation  in the study; 
11. The foreseeable circumstances  and/or reason  under which  the subject’s  participation  in 
the study may  be terminated ; 
12. That the monitors, auditors, the IRB,  and the regulat ory authorities  may  provide direct  
access  to the subject’s  original medical  records.   In such  cases,  the confidentiality  of the 
subject  should be protected,  and by signing and  sealing  an informed  consent  form,  the 
subject  is authorizing such access ; 
13. If the results  of the study are published, the subject’s identity  will remain  confidential; 
14. The anticipated  expenses,  if any,  to the subject  for participating  in the study; 
15. The anticipated  prorated  payment, in  any,  to the subject  for participating  in the study; 
16. The name,  title,  and address  of the investigator to  contact ; 
17. The person(s) to  contact  for further information  regarding the clinical  study and  the rights 
of subjects,  and whom to  contact  in the event of study- related  injury; 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 56 2021.01.30  18. The type of the IRB  engaged  in the assessment  and deliberation  about the acceptability  of 
the study, items  subject  to the assessment  of each  IRB,  and other IRB -related  items  
relating  to the study; 
19. The subject’s  responsibilities.  
10.2.4. Compliance  with  IRB  Regulations 
This study is  to be conduc ted in accordance with  IRB regulations (US  21 CFR Part  56.103) 
regulations.  The investigator  must obtain approval from  a properly constituted  IRB/IEC  
prior to  initiating  the study  and reapproval  or review  at least  annually.  Whitecap  Biosciences  
is to be notified  immediately  if the responsible IRB  has been  disqualified  or if proceedings 
leading  to disqualification  have begun.  Copies of all IRB  correspondence with the 
investigator should be provided to  Whitecap  Biosciences.  
10.2.5. Compliance  with  Good Clinical Practice  
This protocol is  to be conducted in  accordance with  the applicable GCP  regulations and  
guidelines.  
10.3. Changes to the Protocol  
The investigator must not implement any  deviation from  or changes of the protocol without 
approval by Whitec ap Biosciences  and prior review  and documented approval/favorable 
opinion from  the IRB/IEC  of a protocol amendment, except  where  necessary  to eliminate  
immediate  hazards  to study subjects.  
10.4. Documentation  
10.4.1. Source Documents  
Source documents provide evidence for the  existence of the participant  and substantiate  the 
integrity  of the data collected.   Source documents are filed  at the investigator’s site.   Data 
entered  in the eCRF  that are transcribed  from  source documents must be consistent  with  the 
source documents or the discrepancies  must be explained.   The investigator may  need  to 
request  previous medical  records  or transfer  records,  depending on the study. Also,  current  
medical  records  must be available.  
Source documents may  include a subject's medical  records,  hospital charts,  clinic  charts,  the 
investigator's subject  study files,  as well  as the results  of diagnostic tests  such  as X-rays,  
laboratory tests,  and electrocardiograms.   The investigator's copy of the e CRFs  serves  as part 
of the investigator's record  of a subject's study- related  data.  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 57 2021.01.30  The following information  should be entered  into the subject's medical  record  /source notes: 
• Subject’s  contact  information; 
• The date that  the subject entered  the study, subje ct number and  for Part  2, subject  study 
treatment  kit number;  
• Sites  will receive the IWRS  confirmation  notification  for each  transaction.  All 
notifications  are to  be maintained  with  the study source documents; 
• The study title  and/or the protocol number of the study and  the name of Whitecap 
Biosciences;  
• A statement  that informed  consent was  obtained including the date.   A statement  that 
written  authorization (HIPAA  authorization; US  sites  only) and  any local  subject  privacy  
required  documentation for this  study has  been  obtained (including the date)  A statement  
that informed  consent was  obtained (including the date);  
• Reasons  for screen  failure;   
• Dates  of all  subject  visits; 
• All prior and  concurrent  medications  (see Table  7 for definitions and  timeframes).   List  
all prescription and  non-prescription medications  being taken.   At each subsequent visit,  
changes  to the list of medications  should be recorded;  
• All prior and  concurrent  procedures and/or non- medication  treatmen ts (see Table  7 for 
de
finitions and  timeframes ).  List  all procedure and  non- medication  treatments  being 
taken.   At each  subsequent visit,  changes  to the list of medications  should be recorded;  
• Occurrence and  status  of any adverse events  (including onset date,  assessments of 
severity,  seriousness,  and relationship  with  study drug, treatment  instigated  (if any), 
action  taken  regarding study drug, outcome, and  stop date);  
• The date the subject exited  the study, and  a notation as  to whether  the subject completed  
the study or reason  for early  exit; 
• The results  of protocol- required  laboratory tests  performed  by the site  (ie, results  of urine 
pregnancy tests,  hematology including complete  blood count and  differential,  blood 
chemistry  panel  and urinalysis); 
• Patient  medical  and surgical  histories  (including demographics); 
• Patient  ophthalmic history (including iris  color);  
• Results  of physical examination  performed  by site  (including height and  weight); 
• For females,  documentation of non-childbearing potential or results  of pregnancy  test and 
documentation of subject’s  stated  birth  control method when  applicable;  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 58 2021.01.30  • Ophthalmic  examination  results  of subject  visits  including all  IOP measure ments  and 
times,  macroscopic bulbar hyperemia evaluations, pupil size (Part  2 only), visual  acuity,  
contrast  sensitivity  (Part  2 only), slit- lamp  biomicroscopy, visual field  and fundus exams ;  
• S ubject  comfort  of eye drop evaluations responses (Part  2 only); 
• Respiratory  rate,  and temperature measurements  (seated);  
• Postural (supine/standing) blood pressure  and heart  rate; 
• Electrocardiogram  findings;  
• Source notes should also  include any  subject  counseling/education (when  applicable)  
regarding contact  lens usage,  activities  that would interfere with  ocular  surface 
evaluation, permissible  mediations/treatments,  prohibited medications/treatments,  and 
timing  in relation  to scheduled  study visits  and study  compliance including instruction  
provided to  subject  for administration  and storage of study medication.  
10.4.2. Compliance  with  Electronic Records;  Electronic Signatures  Regulations 
This study is  to be conducted in  compliance with the regulations on electronic  records  and 
electronic signature (US  21CFR Part  11).   
10.4.3. Case Report  Form  Completion 
The i nvestigator is  responsible for ensuring that  data are properly recorded  on each  subject’s 
eCRFs  and related  documents.  An investigator who has signed the protocol signature page 
should personally electronically  sign the eCRFs  to ensure that  the observations and  findings 
are recorded  on the eCRFs  correctly  and completely.   A certified  electronic copy of the 
eCRFs  including data corrections  will be provided to the site  for archiving at  the end  of the 
study.  See Study Reference Manual  for eCRF  completion  guidelines. 
10.4.4. D ata Quality  Assurance 
• All participant  data relating  to the study will be recorded  on printed or  electronic  CRF  
unless transmitted  to the sponsor or designee electronically  (eg, laboratory  data).   The 
investigator is  responsible for verifying that  data entries  are accurate and correct  by 
physically or electronically  signing the CRF ;  
• The investigator must maintain  accurate documentation (source  data)  that supports the 
information  entered  in the eCRF ;  
• The investigator must permit study- related  monitoring, audits, IRB/IEC  review,  and 
regulatory agency  inspections and  provide direct  access  to source data documents ;  
• The sponsor or designee is responsible for the data management  of this  study including 
quality checking  of the data;  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 59 2021.01.30  • Study monitors will perform  ongoing source data verification  to confirm  that data entered  
into the e CRF  by authorized  site personnel are accurate,  complete,  and verifiable  from  
source documents; that  the safety  and rights of subj ects are being  protected; and  that the 
study is  being conducted in accordance with the currently  approved protocol and  any 
other study agreements,  ICH  GCP,  and all applicable regulatory requirements. 
10.4.5. Study  and Site Closure 
The sponsor reserves  the right to  close the study site  or terminate  the study at any time  for 
any reason  at the sole discretion  of the sponsor.   
Study sites  will be closed  upon study completion. A study site  is considered closed  when  all 
required  documents and  study supplies have been  collected  and a study- site closure visit has  
been  performed. 
The investigator may  initiate  study- site closure at  any time,  provided there is reasonable 
cause and  sufficient  notice is  given in  advance of the intended termination.  
Reasons  for the early  closure of a study site  by the sponsor or investigator may include but 
are not limited  to: 
• Failure  of the investigator  to comply with  the protocol, the requirements  of the IRB/IEC  
or local  health  authorities,  the sponsor's procedures, or GCP  guidelines; 
• I nadequate recruitment of  subjects  by the investigator; 
• Discontinuation by the sponsor of further development of the study treatment.   
10.4.6. Final  Report  by Investigator 
An investigator's summary , in compliance with  US 21 CFR Part 312.64(c),  will be provided 
to Whitecap  Biosciences  (or designee) within  a short  time  after  the completion  of the study, 
or as  designated  by Whitecap  Biosciences.   A summary  of the study’s outcome is  also to be 
provided to  the responsible IRB  and, if applicable,  the investigator’s institution . 
10.4.7. Retention  of Documentation  
All study- related  correspondence,  subject records,  consent forms,  subject  privacy  
documentation, records  of the distribution  and use of all  investigational products, and  copies  
of case report  forms  should be maintain ed on file.  
For countries falling  within  the scope of the ICH  guidelines, the Whitecap  Biosciences -
specific essential  documents should be retained  until at  least  2 years  after  the last approval of 
a marketing  application  in an ICH  region and until there ar e no pending or contemplated  
marketing  applications in  an ICH  region or at least  2 years  have elapsed  since the formal  
discontinuation of clinical  development of the investigational product.  These documents 
should be retained  for a longer period, however, if  required  by the applicable regulatory 
requirement(s)  or if  needed  by Whitecap  Biosciences.  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 60 2021.01.30  Whitecap  Biosciences  requires that  it be notified  in writing  if the investigator wishes  to 
relinquish ownership of the data so  that mutually  agreed -upon arrangements  can be made for 
transfer  of ownership to  a suitably  qualified, responsible person. 
10.5. Monitoring by Whitecap  Biosciences  
Authorized representatives  of Whitecap  Biosciences  will monitor the study on a periodic 
basis.   The determination  of the extent , frequency  and nature of  monitoring will be based  on 
such as the objective,  purpose, design, complexity,  blinding, size,  and endpoints of the study.   
Authorized representatives  of Whitecap  Biosciences  or regulatory  authority representatives  
will conduct on- site visits  to review,  audit and  copy  study- related  documents.  These 
representatives  will meet  with  the investigator(s) and appropriate staff  at mutually  convenient 
times  to discuss study- related  data and questions. 
10.6. Publications  
The resu lts of this  study may  be published or presented  at scientific  meetings; the 
investigator shall  agree to  submit all  manuscripts or abstracts  to the sponsor before 
submission.  This allows  the sponsor to  protect  proprietary  information and  to provide 
comment s.  
The sponsor will comply with  the requirements  for publication of study results,  in accordance 
with standard  editorial and  ethical  practice.   Whitecap  Biosciences,  as the sponsor, has  
proprietary  interest in  this study and  thus will be involved in  reviewing, at  a minimum,  any 
abstract  or manuscript prior to  submission in  order to  allow  the sponsor to  protect  proprietary  
information  and to provide comments.   Authorship and  manuscript composition  will reflect  
joint cooperation between  the investigator(s) and Whitecap  Biosciences  personnel.  
Authorship will be established  prior to  the writing  of abstracts  or manuscripts,  will be 
determined  by mutual agreement,  and in line with  International Committee  of Medical  
Journal Editors authorship requirements.  
As this study involves multiple  centers,  no individual publications will be allowed  prior to  
completion  of the final  report  of the multicenter  study, except  as agreed  with  Whitecap  
Biosciences.   
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 61 2021.01.30  11. References  
AGIS  (The  Advanced  Glaucoma Intervention Study). The relationship between  control of  
intraocular  pressure and visual field  deterioration. The AGIS  Investigators. Am J 
Ophthalmol. 2000;130(4):429-440. 
Burke J,  Schwartz M.  Preclinical  evaluation  of brimonidine. Surv  Ophthalmol. 1996;41 
Suppl 1:S9-18. 
Heijl A, Leske MC,  Bengtsson B,  Hyman  L, Bengtsson B,  Hussein  M, et al. Reduction of 
intraocular  pressure and glaucoma progression: results  from  the Early  Manifest  Glaucoma 
Trial.  Arch  Ophthalmol.  2002;120(10):1268-1279. 
ICH M3 guidance and UK Clarification  of Contraceptive Wording in  Clinical  Trials  
Conducted in  the UK (21  May  2010).   
Jabs DA,  Nussenblatt RB,  Rosenbaum JT;  Standardization  of Uveitis  Nomenclature (SUN) 
Working Group.  Standardization of uveitis  nomenclature for reporting  clinical  data.  Results  
of the First  International Workshop. Am J Ophthalmol. 2005;140(3):509-516. 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 62 2021.01.30  12. Attachments  
12.1. Glossary of Terms,  Abbreviations and Definitions  
Table  7 Glossary of Terms  and Abbreviations 
Term/Abbreviation  Definition  
ANOVA/ANCOVA  Analysis  of Variance/Analysis  of Covariance  
BAK benzalkonium  chloride  
BCVA  best-corrected  visual  acuity  
BID twice  daily 
bpm beats  per minute  
BUN  blood  urea nitrogen  
C/D cup/disc  
CRF/eCRF  case  report  form/electronic  case  report  form 
ECG  electrocardiogram  
eDC Electronic  data capture  
FDA Food  and Drug  Administration  
GAT Goldmann  Applanation  Tonometer  
GCP  Good  Clinical  Practices  
GI gastrointestinal  
HIPAA  Health  Insurance  Portability  and Accountability  Act 
ICH International  Conference  on Harmonisation  
IEC Independent  Ethics  Committee  
IETD  investigator  emergency  treatment  disclosure  
IOP intraocular  pressure  
IP investigation  product  
IRB Institutional  Review  Board  
IWRS  Interactive  web-response  system  
LogMar  logarithm  of the minimum  angle  of resolution  
MAOI  monoamine  oxidase  inhibitor  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 63 2021.01.30   
Term/Abbreviation  Definition  
MedDRA  Medical  Dictionary  for Regulatory  Activities  
mITT  Modified  intent -to-treat 
mm Hg millimeters  of mercury  
NOAEL  no observed  adverse  effect  level 
OHT  ocular  hypertension  
OU both eyes  
PGA  prostaglandin  analog  
POAG  primary  open  angle  glaucoma  
PP per protocol  
RGP  rigid gas permeable  
SITA  Swedish  Interactive  Thresholding  Algorithm  
SNRI  serotonin  norepinephrine  reuptake  inhibitor  
TCA tricyclic  antidepressant  
US United  States  
 
  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 64 2021.01.30  Table  8 Glossary of Definitions  
Term  Definition  
End of Study  The date of the last visit of the last subject  in the study  
Subject  Status  Subject  status  is defined  below : 
Study  entry  A subject  who has signed  informed  consent  and has undergone  at least  1 
screening  procedure and been  entered into IWRS  
In screening  A subject  who has is undergoing  the screening  process  and has not yet qualified  
for study  enrollment.  
Screen  failure  Subject  who has signed  informed  consent,  has undergone  at least  1 screening  
procedure,  but fails  to qualify  for study  at any time  prior  to and  up until  the 
completion  of the Baseline  visit. 
Enrolled  A subjec t who qualifies  for study  based  on Inclusion  and exclusion  criteria  (Parts  1 
and 2) (see  Sections  4.1 and  4.2) AND is randomized  (assigned  a randomization  
number  (Part  2). 
Subject  completion  A subject  who has completed  all phases  of the study  including  the last scheduled  
procedure  as shown in  the Schedule  of Visits and  Procedures.  
“Should”  vs “Must”  Use of the word  “should”  means  that it is suggested  or recommended,  but not 
required,  whereas  the use of the word  “must”  means  that it is required.  
Concurrent  Medication  A medication  that the study  subject  is taking  at the time of enrollment  or after 
Concurrent  Treatment  A procedure  or other  non-medication  medical  treatment  that the study  subject  is 
receiving  at the time  of enrollment  or after. 
eg, for example  
ie, in other  words  
Prior  Medication  A medication  taken  by the study  subject  within  time period  specified  in entry  
criteria  prior  to enrolling  in the study.  Other  prior  medications  within  3 months  
prior to enrolling into  the study.  
Prior  Treatment  A procedure  or other  non-medication  medical  treatment  received  by the study  
subject  within  time  period specified  in entry  criteria  prior  to enrolling  in the study.  
Other  prior  treatments  within  3 months  prior  to enrolling  into the  study.  
Study  eye The designated  eye for use in analysis  of IOP effects  will be based  on the eye 
with the higher  IOP at Day -1, Hour  0.  If both  eyes  qualify,  the eye with the higher  
IOP at Baseline (Day  -1) Hour  0 will be  the study  eye.  If both  eyes  have the same  
IOP value  at this timepoint,  the right eye will be the study  eye. 
  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 65 2021.01.30  12.2. Examination  Procedures,  Tests,  Equipment, and Techniques   
Study evaluations should be performed  by the same investigator or sub-investigator 
throughout the study whenever  possible.  If  it is not possible to  use the same individual to  
follow the subject,  then  an attempt should be made to  have visits  overlap  (examine the 
subject  together and  discuss findings) for at  least  one visit.   At designated  study visits,  
physical examinations and  the comfort  of eye drop subject  questionnaire should be conducted 
prior to  other assessments or invasive procedures.  Data will be recorded  on the appropriate 
eCRF.  
12.2.1. Demographics  and Baseline  Characteristics  
Demographic information  including age,  race (including limited  ethnicity) , gender and  iris 
color are to  be obtained at the screening  visit.  
12.2.1.1. Medical  and Ophthalmic  Histories  and Procedures  
Medical  (relevant)  and ophthalmic  history (including the histo ry of the current  
disease/disorder ), any  pertinent procedures that  could  potentially  influence the safety  of the 
subject  and/or the outcome of the study and  any information regarding underlying 
disease/disorders  are to  be obtained at  Screening .  Data will be recorded  on the appropriate 
eCRF.    
12.2.1.2. Physical Examination (Including  Height  and Weight) 
The subject  will be examined  for any  detectable  abnormalities  of the following body 
systems:   general  appearance;  head, eyes,  ears,  nose and  throat (HEEN T); 
heart/cardiovascular;  lungs; abdomen; neurologic; extremities; back;  musculoskeletal; 
lymphatic  and skin. 
Height will be measured  (without shoes) in  inches  (in) or centimeters  (cm).   Weight (without 
shoes) will be measured  in pounds (lb) or kilograms (kg) using a scale.   Historical subject  
information  and/or subject reports  should not be used  for the height an d weight 
measurements.  
12.2.1.3. Respiratory  Rate  and Temperature  
Respiration  rate will be measured  after the subject has  been  in a resting  state  (seated)  for at 
least 5 minutes.   Respiration  rate will be counted for 30 seconds, multiplied  by 2, and  
recorded  as breaths per minute.   Temperature will be measured  after  the subject  has been  in 
a resting  state  (seated)  for at  least  5 minutes.   Temperature will be measured  in Celsius  (°C) 
or Fahrenheit  (°F).  Oral,  Skin or tympanic temperature methods of collection  are acceptable.  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 66 2021.01.30  12.2.1.4. Postural (Supine  / Standing)  Blood  Pressure and Heart  Rate   
Postural Systolic/diastolic  blood pressure  and heart  rate will be measured  after  the subject  
has been  in a resting  state  (supine) for at  least  5 minutes and  then  again  3 minutes  after  
standing.  Record  the 2 measurements  from  the 2 positions (supine and  standing).   Pulse will 
be counted for 30 seconds,  multiplied  by 2, and  recorded  in bpm. 
12.2.1.5. Urine Pregnancy  Test  
Female subjects  who  are of child -bearing potential (see Section  6.4 for definition) will have a 
urine pregnancy  test performed.  Pregnancy  test kits will be provided by a qualified  third -
party  vendor (see  Attachment  12.4) and  will be administered  according  to the instru ctions 
provided with  the tests.  
12.2.1.6. 12 lead-ECG  
Sites  will receive training  on the use of ECG  equipment provided.   
[Triplicate]  12-lead ECG  will be obtained using an  ECG  machine that  automatically  
calculates  the heart  rate and measures  PR, QRS,  QT, and [QTc]  intervals.   At each  time  point, 
3 individual ECG  tracings  should be obtained as  closely  as possible in  successio n, but no 
more  than  2 minutes  apart.  The full set of triplicates  should be completed  in less than  4 
minutes.   
12.2.1.7. Clinical Safety  Laboratory Assessments (non -fasting) 
The investigator must review  the laboratory  report,  document this  review,  and record  any 
clinically  relevant  changes  occurring during the study in  the AE section  of the e CRF.   
Clinically  significant abnormal laboratory findings are those which  are not associated  with  
the underlying disease,  unless  judged by the investigator to  be more  severe than expected  for 
the participant's condition.  The laboratory reports  must be filed  with  the source documents.   
All laboratory tests  with  values  considered  clinically  significantly  abnormal during 
participation  in the study or within  [insert  timeframe]  after  the last  dose of study treatment  
should be repeated  until the values  return  to normal or baseline or are  no longer considered  
clinically  significant by the investigator or medical monitor. 
• If such values  do not return  to normal/baseline  within  a period of time  judged reasonable 
by the investigator, the etiology should be identified  and the sponsor notified; 
• All protocol- required  laboratory  assessments (see below) must be conducted in  
accordance with  the L aboratory  Manual  and the Schedule of Visits  and Procedures;  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 67 2021.01.30  Laboratory assessments will include blood chemistry  panel,  hematology including complete  
blood count with  differential,  urinalysis and  urine pregnancy test  for all  females  who  are of 
child -bearing  potential (See Section  6.4 for definition).  
The specific tests  in these panels  are: 
Complete  Blood Count  (with  differential):  hematocrit,  hemoglobin, red  and white  cell 
count, mean  corpuscular volume (MCV),  mean  corpuscular  hemoglobin (MCH),  mean  
corpuscular hemoglobin concentration  (MCHC),  red blood cell  morphology, reticulocyte  
count, platelet  count, neut rophils (bands and  segments),  lymphocytes, monocytes, 
eosinophils, and  basophils. 
Chemistry  Panel :  albumin/globulin  (A/G  ratio),  alanine aminotransferase  (ALT),  aspartate 
aminotransferase (AST),  gamma -glutamyl transpeptidase (GGT),  albumin, alkaline  
phosphatase,  bilirubin  (total,  direct,  and indirect),  blood urea nitrogen (BUN),  
BUN/creatinine  ratio,  calcium,  magnesium, cholesterol,  high-density lipoprotein (HDL),  
low-density lipoprotein (LDL),  chloride, creatinine,  globulin, hemoglobin A1c (HbA1c),  
lactic  dehydrogenase (LDH),  phosphorus, potassium, serum  bicarbonate,  total protein, 
sodium, triglycerides,  uric acid,  and creatine phosphokinase (CPK).    
Urinalysis :  A urine specimen  will be collected  and assessed  for color (appearance),  specific 
gravity, pH,  glucose, protein, ketone, urobilinogen, nitrite,  leukocyte esterase,  occult  blood, 
and bilirubin.  Microscopic analysis  includes the following:  red  blood cells  per high power 
field (RBC/HPF),  white  blood cells  per high power field  (WBC/HPF),  squamous epithelial  
cells;  additional components, abnormal and/or atypical  cells  will also  be reported  if present.    
Urine pregnancy  test:  All females  who  are of child -bearing  potential are  required  to have 
urine pregnancy  tests.  
Handling  of Biological Specimens :  Samples  of blood and  urine for evaluation  of 
hematology, chemistries  and urinalysis will be analyzed  at a centralized  clinical  laboratory 
with certification  from  a recognized  accreditation  agency  (eg, College of American  
Pathology [CAP] or Clinical Laboratory Improvement Amendments [CLIA] certification).   
12.2.2. Ophthalmic  Examination Procedures,  Tests,  Equipment,  and Techniques   
Visits  for ophthalmic examinations should be scheduled  at approximately the same time  of 
the day.   A gross general  examination  of the external  eye and  adnexa should be performed,  
and pathology described.   See the Schedule of Visits  and Procedures  (Tables  1, 2 and  3) for 
the order in  which  the procedures should be  performed.  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 68 2021.01.30  12.2.2.1. Subject  Comfort of Eye Drops  Evaluation (Questionnaire)  (Part  2 only) 
Subjects  will be asked  questions by a designated  clinical  staff  member  at the site  to assess the 
study medications  by responding to  a series  of questions regarding their  comfort  of the ir IOP-
lowering medications.   Conduct these interviews  in a quiet place with only the study 
participant  and the interviewer  present.   Please instruct each  subject  that his/her input is  
important.  S ubjects  should report  on their  experiences  and impressions (ie,  there are  no 
“right” or “wrong” answers).   Begin  with  asking the subject  about all  of the  symptoms s/ he 
may be experiencing or overall  comfort  in the right eye and  then  when  complete,  ask about 
the symptoms of the left  eye.  
Subjects  will be asked  questions by a clinical  staff  member  at the site  to assess  the comfort  of 
their eye drop medication(s)  (for each eye) : 
• (if applicable)  the IOP -lowering  medication  they  are taking prio r to entry  into the study 
(at Screening); 
• the study medication  (at post- Baseline visits) . 
Leading  Question  at Screening:   Thinking about your <appropriate> eye, how would you 
rate the overall comfort  of your current  glaucoma eye drops? 
Leading  Qu estion  at Study  Visits:   Thinking about your <appropriate> eye, how would you 
rate the overall comfort  of the study eye drops? 
Using  t he Subject  Comfort  of Eye  Drops Questionnaire on a 6-point scale,  read  to the subject  
each of the  responses for the selection  that best matches  their  experience:   Very  comfortable,  
Comfortable, Slightly  uncomfortable, Uncomfortable, Very  Uncomfortable,  Intolerable.  
12.2.2.2. Macroscopic Bulbar  Conjunctival  Hyperemia  
The macroscopic (gross) hyperemia  grading should  be completed  prior  to any other  eye 
examinations .  Bulbar hyperemia will be graded  by the Investigator upon gross inspection 
under consistent illumination  by comparing the appearance of  the bulbar conjunctiva to  
standard  photographs.  
  0 (None)  = Normal.  Vessels  of bulbar  conjunctiva  easily observed  
+0.5 (Trace)  = Trace  flush,  reddish -pink color 
+1 (Mild) = Mild flush,  reddish  color 
+2 (Moderate)  = Bright  red color 
+3 (Severe)  = Deep,  bright  diffuse  redness  
The gross macroscopic hyperemia evaluation  should be performed  by the same evaluator  in 
the same facility  with  consistent lighting  throughout the entire  study, whenever  possible.  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 69 2021.01.30  12.2.2.3. Visual  Acuity  
Manifest  refraction  will be performed  at specified  study visits (See the Schedule of Visits  and 
Procedures  Tables 1, 2, and 3 in  the protocol synopsis and  see Section  8) to  obt ain a 
correction  for all  visual acuity  evaluations.  Visual  acuity  (in Snellen  equivalents) will be 
measured  for each  eye using a logarithmic  (LogMar) visual acuity  chart  for testing  at 4 
meters.   Please refer  to the Study Reference Manual  for details  on the procedures for 
measuring  visual acuity . 
12.2.2.4. Pupil  Size  (Part  2 only) 
Pupil size for each  eye will be measured  using the centimeter  ruler on the near  card,  measure 
the subject's undilated pupils to  the nearest  0.5 mm in  size.   The pupil gauge on the near  card  
may be used  instead  per investigator preference.   The size of the pupil will  be measured  prior 
to biomicroscopy and  IOP evaluations. 
12.2.2.5. Contrast Sensitivity  (Part  2 only) 
Contrast Sensi tivity  will be measured  using the VectorVision  CSV -1000 test  at four levels  of 
contrast .  The test distance for the chart  must be kept consistent throughout the  study.  Do  not 
set up chart  in brightly lit room or sunlight.  Details  for the operation of the equipment and  
the conduct of the test  for each  patient  can be found in  the Study Reference Manual . 
12.2.2.6. B iomicroscopic Examinations 
Findings other than  those listed  below should be recorded  under “other” for the appropriate 
location  of the finding.  Required  dilated  examinations  are designated  on the Schedule of 
Visits  and Procedures.  
Eyelid/Eyelid  Margins/Lashes  
Edema     
  0 (None)  = No edema  
+0.5 (Trace)  = Localized,  minimal  (trace)  swelling  
+1 (Mild)  = Localized,  mild swelling  
+2 (Moderate)  = Diffuse,  moderate  swelling  
+3 (Severe)  = Diffuse,  severe  swelling  
Erythema    
  0 (None)  = No erythema  
+0.5 (Trace)  = Localized,  minimal  (trace)  flush  reddish  color   
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 70 2021.01.30  +1 (Mild)  = Localized,  mild,  flush  reddish  color  
+2 (Moderate)  = Diffuse  reddish  color  encompassing  the entire  lid margin  
+3 (Severe)  = Deep  diffuse  reddish  color  of lid margins  and superior  and/or  inferior  
eyelid  
Conjunctiva  (Bulbar)  
Hyperemia     
  0 (None)  = No hyperemia  
+0.5 (Trace)  = Minimal  (trace)  flush,  reddish  color  
+1 (Mild)  = Mild flush,  reddish  color  
+2 (Moderate)  = Bright  red color  
+3 (Severe)  = Deep,  bright  diffuse  redness  
Edema     
  0 (None)  = No edema  
+0.5 (Trace)  = Localized,  minimal  (trace)  swelling  
+1 (Mild)  = Localized,  mild swelling  
+2 (Moderate)  = Diffuse,  moderate  swelling  
+3 (Severe)  = Diffuse,  severe  swelling  
 
Cornea  
Edema     
  0 (None)  = No edema 
+0.5 (Trace)  = Localized,  minimal  (trace)  epithelial  haze  
+1 (Mild)  = Dull glass  appearance  of epithelium  that may include  fine localized  
microcystic  changes  
+2 (Moderate)  = Dull glass  appearance  of the epithelium  with large  number  of cystic  
changes  with or without  stromal  edema  
+3 (Severe)  = Epithelial  bullae  and/or  stromal  edema,  localized  or diffuse,  with or 
without  stromal  striae  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 71 2021.01.30  Superficial  Punctate  Keratopathy  
  0 No superficial  punctate  keratopathy  
+0.5 (Trace)    
+1 (Mild)    
+2 (Moderate)    
+3 (Severe)    
Anterior  Chamber  
For the measurements  of cells and flare based  on standardized  uveitis  nomenclature 
(SUN Working Group, 2005),  the following settings  should be used: 
1 x 1 mm slit  High magnification  
Highest  slit lamp  voltage   Low ambient  lighting  
Illumination  angle  of 45 degrees  Same  grader  and slit lamp  whenever  possible  
Cells 
  0 = 0 cells  
+0.5 = 1-5 cells (trace)   
+1 = 6-15 cells 
+2 = 16-25 cells 
+3 = 26-50 cells 
+4 = >50 cells 
Flare 
  0 = None:  No flare seen 
+1 = Faint:   Faint  flare seen 
+2 = Moderate:    Iris and lens details  clear 
+3 = Marked:    Iris and lens details  hazy 
+4 = Intense:    Fibrin  or plastic  aqueous  
 
Iris/Pupil  
The iris/pupil will be evaluated  for pathology.  If pathology is  present,  it will be described.  
Iris Color (Screening  only)  
Iris color will be recorded  at Screening  using the following classification:  blue, blue- gray,  
blue/gray-brown, gray,  green,  green -brown, hazel,  brown, dark  brown, or other (specify).  
12.2.2.7. Intraocular Pressure (IOP) (mm  Hg)  
IOP s hould be measured  only after  the biomicroscopic exam  is comple ted and must be 
measured  prior to  pupil dilation.   IOP  measurements  will be taken  by two  qualified  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 72 2021.01.30  independent study site  personnel using a Goldmann applanation tonometer (GAT)  affixed  to 
a slit lamp  with  the subject  seated.   One  person will adjust the dial in  masked  fashion while  a 
second  person will read  and record  the value.   The subject  and slit lamp  should be adjusted  so 
that the subject ’s head  is firmly  positioned on the chin  rest and against  the forehead  rest 
without leaning  forward  or straining.  Tight fitting  neckwear  should be loosened.  Both eyes  
will be tested,  with  the right eye preceding the left  eye.   Each  IOP measurement  is to be 
recorded.  
One person (“the measurer”)  looks through the binocular viewer  of the slit  lamp  at low 
power.  The tensi on knob is  pre-set at a low- pressure  value (4 to 6 mm Hg).   The measurer  
follows the image  of the fluorescein -stained  semicircles  while  he/she slowly  rotates  the 
tension knob until the inner  borders of the fluorescein  rings touch each  other at  the midpoint 
of their  pulsation in  response to  the cardiac cycle.   When  this image  is reached,  the measurer  
takes  his/her fingers  off the tension knob and  the second  person (“the reader”)  records  the 
IOP reading along with  the date and  time  of day  in the source document, thus maintaining  a 
masked  IOP reading.  For a given subject,  the reader  should not also  be the person to  
dispense/administer/discuss  study medications  with  the subject.  
At least two,  and if necessary,  three consecutive measurements  will be taken  to determine  
IOP in the manner  described  above.  If  the first  two measurements  differ  by 2 mm Hg  or less,  
a third  measurement  is not required, and  the two measurements  will be recorded.  If the first 
two measurements  differ  by more  than  2 mm Hg,  a third  measurement  should be made,  and 
all three measurements  will be recorded.  
12.2.2.8. Visual  Field  
Measure the subject ’s pupils (to  the nearest  0.5 mm).   If they  are less than  3 mm in  diameter,  
dilate  them  with  2.5% phenylephrine drops, unless contraindicated.   If the brow  is heavy  or 
the upper lid  is drooping, tape accordingly.  Visual  field  results  must be reliable (ie,  ≤ 33% 
fixation  losses,  false positive or false negative errors) or the field  should be repeated  within  
two weeks.   Visual  field examinations will be performed  using a Humphrey automated  
perimetry  test (24-2) using the full  threshold or SITA  standard  testing method).  The same 
test method (eg,  SITA  Standard  24-2) should be used  for all  visual fields  for a given subject , 
including the historical visual field,  if applicable.   Preferred  equipment is  the Humphrey 700 
Humphrey Field  Analyzer  (HFA)  2 series  machi nes (eg,  740 or 750).  Visual  fields  will be 
reported  as normal or abnormal  and the mean  deviation  will also  be recorded  in decibels  
(dB).  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 73 2021.01.30  Begin  by testing  the right eye.   Adjust the chin rest and the table  height as  needed  to achieve 
proper alignment as  well as to maintain  the subject  in a comfortable seated  position 
throughout the test.   It is permissible  to encourage  the subject  occasionally  if the subject  
seems  to be fatigued  or losing concentration, and  to allow  the subject  to pause and  rest if 
necessa ry.  The subject  should also  be informed  that a good time  to blink is  when  the 
response button is  pushed so  as not to  affect  the results  of the test.  
12.2.2.9. Other Ophthalmic  Examinations  
Use biomicroscopic examination,  indirect  lenses,  direct/indirect ophthalmoscopy, etc.  as 
appropriate to  visualize.  
Lens  
Lens  Status  
Lens  status  will be assessed  as phakic, pseudophakic, or aphakic.   The lens (including the 
posterior capsule for subjects  who  have undergone lens  extraction)  will also  be evaluated  for 
pathology.  If pathology is  present,  it will be described.  
Cataract  A ssessment  (phakic eyes  only) 
Under dilated  examination,  the presence and  severity  of nuclear,  cortical  and posterior 
subcapsular cataract  lens opacities  will be evaluated.   At the first  dilated  examination,  each  
type of cataract,  if present,  will be graded  using the scale below.   At the last  follow-up dilated  
examination, each  type of  cataract  will be assessed  for change from  baseline and  if changed,  
the current  severity  will be graded  using the scale  below:  
  0 = None 
+1 = Mild 
+2 = Moderate  
+3 = Severe  
Vitreous  
The vitreous will be evaluated  for pathology.  If pathology is  present,  it will be described.   
Note  if the condition is  not evaluable.  
Fundus  
The fundus (posterior pole; periphery, when  dilated) will be evaluated  for pathology.  If 
pathology is  present,  it will be described.   Note  if the condition is  not evaluable.   
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 74 2021.01.30  Optic  Nerve  
The optic nerve will be evaluated  for pathology.  If pathology is  present,  it will be described.   
Note  if the condition is  not evaluable.   
Cup/disc ratio  will be reported  using a 0.0 to  1.0 scale.   The Armaly  chart  provided by 
Whitecap  Biosciences  provides a pictorial scale of cup/disc ratio  of 0.0 to  0.8.  Note  if the 
condition  is not evaluable.  
12.3. Other Study  Supplies   
As needed,  Whitecap  Biosciences  will provide logarithmic  visual acuity  charts  as necessary , 
the Armaly  chart  (for measurement  of cup/disc ratio),  and the bulbar hyperemia grading 
guide (standard  photographs).  In  addition, ECG  equipment will be provided to  each  site as 
needed.   Contrast sensitivity  equipment will be provided to  designated  sites .  Study sites  are 
to use their  own  equipment for all  other examinations  and measures.  
The kits for collection  of non-f asting  clinical  laboratory analysis,  as well  as urine pregnancy  
test kits will be provided a qualified  third -party  vendor (see  Attachment  12.4): 
• Laboratory kits  (including pregnancy tests)  for the collection  and shipment of blood and  
urine samples.  
• Shipping materials  for shipment of laboratory samples  to the central  laboratory.  
12.4. List of Computerized  Systems 
Electronic Data  Capture  (EDC)  
This pr otocol will use eCRFs  using remote  eDC  through a qualified  third -party  vendor.  The 
data will be entered  on the  eCRFs  in a timely  manner  on an  ongoing basis.   Data will be 
located  in a study- specific clinical  database.   Service Provider:  iMednet   Location:  Lowell,  
MA USA.  
Interactive  We b-Based  Response  System  (IWRS) 
The IWR S, a module of the eDC , will be used  to confirm  Baseline IOP  eligibility  and in Part 
2 only, stratification,  randomization and  medication  kit numbers assignment.  The IWR S will 
also be used  to manage study medication  inventory.  Service Provider:  iMednet, Location:  
Lowell,  MA USA.  
Clinical Laboratory Sample  Analysis 
Analysis of laboratory samples:  blood chemistry  panel,  hematology including complete  
blood count with  differential,  urinalysis, and  urine pregnancy tests  for all  females  who  are of 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 75 2021.01.30  child -bearing  potential will be performed  by a qualified  third -party  vendor.  Service Provider:  
LabCorp; Location:  Burlington, North  Carolina, USA. 
12.5. Protocol  Amendment s 
12.5.1. Amendment  1 Summary  
Study  Title :  A Phase 1/2a Assessment  of WB007  Ophthalmic  Solution in  Subjects  with  
Primary  Open -Angle Glaucoma or Ocular  Hypertension 
Protocol  WB007-001_01 (Amendment 1);   Date  of Amendment :  July 2019 
 
Section  Revision Rationale 
Synopsis  Study  Population:  Adult  (at least 18 years  of age) male  
or female subjects  with primary  open -angle  glaucoma  or 
ocular  hypertension  in each eye who are otherwise  in 
generally  good  health.   Only  one eye must  meet  all ocular  
entry  criteria.   Clarified that only one eye must 
meet all ocular entry criteria to 
participate in the study.   
Dosage/Dose  Regimen  (Part  2):  added “Site  personnel  
will administer  the morning dose at study visits.”  Added emphasis here that site 
personnel will administer doses 
at study visits.  
Randomization/Stratification :  added  “When  both eyes 
qualify,  the study eye will be defined  using the 
Interactive  Web  Response  System  (IWRS), a module  
within  the electronic  data capture (eDC)  system.”  Clarified use of IWRS during randomization  
Synopsis, Sections 9.3.1.1 
and 9.4  Primary  analysis:   The  primary  analyses  will be 
performed  in the mITT  population via analysis  of 
covariance (ANCOVA)  tests which  will have  treatment  
as the main  effect  and the baseline  hour-matched  IOP as 
the covariate in the model.    This  approach will also be 
used  on “Other  analyses” of IOP values  at Day 14 and 
Mean  Diurnal  IOP at Day 14. Accepted FDA suggestion to 
change primary analysis.  
Original primary analysis will 
now be secondary.  Other  
Sections 3.2, 5.1.1, 7.5, 8.3.2, 
12.4 An interactive  web response  system  (IWRS), a module  
within  the Electronic  Data  Capture  (eDC)  system  will be 
used to select  study eye and manage the treatment 
assignment  process,  including  subject  randomization  and 
stratification  in Part 2. Clarified how IWRS will be 
used in this study  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 76 2021.01.30  Section  Revision  Rationale  
Section 3.2.2.  Part 2: Subject  treatment  will be double -masked;  neither  
the investigator  nor the staff or subject  will be aware of 
treatment  assignment.   All study treatments  will be 
provided in similarly -appearing  bottles  and identical 
cartons  to maintain  masking of the study.  The study treatments will not 
be in identical bottles , but in 
similar -appearing bottles with 
the same colored bottle caps .  
The bottles will be packaged in 
identical unit cartons.  
Tables 1, 2, 3; 
Section 7.3, 8.2, 8.3, 8.4, 10.4.1, 12.2.1.3, 12.2.1.4  “Vital Signs” has been removed.  Respiration rate and temperature have been separated from “Postural blood pressure and heart rate”.
   Clarify seated vs. supine and standing measurement s.  The 
use of the term “vital signs” became superfluous.  
Table 1  Removed  footnote  d: 
 “At Day 1 Hour  0, if IOP has changed  by more  than 3 
mm Hg from  Baseline  (Day  -1) Hour  0, the subject  is not 
eligible. ”  Decision to simplify entry criteria and alignment between Parts 1 and 2.  
Table 3, Section 
8.4.2  Subject  Comfort  of Eye Drops  Evaluation  (administered  
by designated  site personnel)  (Day  14/Exit  only)  Clarified that evaluation will be performed at Day 14 only (not 
Days 7 AND 14)  
Table 3, Sectio n 
8.4.2  Added  footnote  e to table:   “Give  study  medication  to 
subject  at the end of the visit”  and clarified  language  in 
Section  8.4.2  
 Clarify in Part 2 that subject 
will be given the study 
medication at the end of the Day 1 visit.  
4.2 • Removed  exclusion  criterion  #9 
• Removed  exclusion  criterion  #10  Original criteria 10, 11 and 12 
were sub -bullets of Criterion 
#9.  A formatting issue occurred which elevated criteria 10, 11 and 12 to same level as 9, rendering 9 unnecessary.   Criterion #10 was a duplicate of criterion #2.  
4.2 Exclusion  #33 was modified  to allow  subjects  with up to 
+1 (mild)   conjunctival  hyperemia  (rather  than up to +0.5 
(trace)  to screen  for this study.     Loosened the criterion to 
ensure efficient enrollment of 
this study population without 
jeopardizing the o utcome of the 
study.   
Tables 1, 3; 
Sections 7.3, 8.3, 
10.4.1  Pupil  size will be measured  before  visual  acuity  Aligns with common practice  
8.4.1  Part 1 – Day 1 (Hour  0):  added  a bullet  for study  
medication  assignment   
8.4.2  Added  bullet  to Part 2 – Evening before  Day 7 and Day 
14 (Exit):   “Contact  from  site to remind  subject  to dose 
study medication  approximately 12 hours  prior  to Hour  0 
appointment  time.”  Clarified in this section to align 
with Table 3 and Sections 
5.2.1, 8 and 8.6  
8.4.2 and 8.6  Added  bullet  to Part 2 - Days  7 and 14/Exit  (Hour  0) (±10 
minutes): “Site  to collect  study medication  following  
final dose (Day  14/Exit  only)”  Clarified when study 
medications will be collected 
from the subject in Part 2.  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 77 2021.01.30  Section  Revision  Rationale  
8.6 Added  to Subject  Instructions:   “To avoid  discussing  side 
effects  (if any experienced)  with other  subjects  in the 
study”  and in Part 2: 
“The study medications  should be kept in their unit 
carton  (box).   Do not show  the bottles  to other  subjects  or 
study staff (except  the individual  who dispenses  the study  
medication  to the subject.”  To minimize bias  
9.3.1.2  Moved  analysis  of variance  to secondary  efficacy  
endpoint  To accommodate updated 
primary analysis.  
10.1.3  Rephrased the 4th bullet:  
If the ICF is modified during the s ubject’s participation in 
the study, subjects must be re -consented to the most 
current version of the ICF(s).   Previous wording was 
confusing.  
12.2.2.4  Pupil Size methodology clarified to remove pupillometry 
and accept the use of a near card.  Methodology section aligned 
with main body of protocol.  
12.2.2.7  For a given subject, the reader should not also be the 
person to dispense/administer/discuss study medications 
with the subject.  To minimize bias  
12.5.2. Amendment  2 Summary  
Study  Title :  A Phase 1/2a Assessment  of WB007  Ophthalmic  Solution in  Subjects  with  
Primary  Open -Angle Glaucoma or Ocular  Hypertension 
Protocol  WB007-001_02 (Amendment 2);   Date  of Amendment :  Sept 2019 
Section  Revision  Rationale  
4.1 IOP in fellow eye at Baseline ≤ 34 mm Hg at Hour 4 
added.   Inadvertently omitted Hour 4. 
4.1, 7.3 and 
12.2.2.3, 12.3  Visual Acuity  (VA) :  replaced testing distance of 3 
meters to 4 meters ; removed distance from entry 
criterion ; visual acuity charts will be provided to sites as 
necessary. Testing distance of 4 meters is 
a standard practice with 
logarithmic VA charts.  
 
Distance for VA testing is 
redundant in inclusion criterion.  
 
Logarithmic VA charts will be 
provided as necessary.  
8.2 Clinical laboratory evaluation (non- fasting), “including 
CBC with differential, Blood Chemistries, Urinalysis” 
added.  Clarified that both blood and 
urine specimens will be 
collected.  
8.4.2  Part 2, Day 1, 30 minutes Subject Comfort of Eye Drop Evaluation was added  Examination inadvertently 
omitted in the text.  
8.4.2  Part 2, Days 7 and 14/Exit Hour 2 Visual Field 
examination is to be performed at Day 14/Exit only.  
Part 2, Days 7 and 14/Exit Hour 8 Fundus examination is to be performed at Day 14/Exit only.  Clarified that these 2 examinations are to be performed at Day 14/Exit only.  
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 78 2021.01.30  12.5.3. Amendment  3 Summary  
Study  Title :  A Phase 1/2a Assessment  of WB007  Ophthalmic  Solution in  Subjects  with  
Primary  Open -Angle Glaucoma or Ocular  Hypertension 
Protocol  WB007-001_03 (Amendment 3);   Date  of Amendment :  Jan uary 2020 
Section (s) Revision  Rationale  
Synopsis, Table 3, 
Figure 3;  
Sections 8, 8.4.2, 8.6, and 9.3.2  Moved Day 7 to Day 4  Assess potential to observe 
early steady state 
Synopsis, Table 3, Figure 3; Sections 
8 and 8.4.2  Removed Day 2 -3 required phone call  Phone call now optional.  
Synopsis  Schematic of study design for Part 2 modified duration of 
diurnal days from 12 to 8 hours  Align with protocol text . 
8.3.2.  Removed “Hour 0” from IOP required to enter into IWRS.  All Baseline IOP needs to be entered prior to 
randomization.  Align with inclusion criteria 3e 
and 3f 
Table 3; Sections 
5.1.1  and 8.4.2  IP kits for Part 2 will include 2 bottles , each in a unit 
carton.  Secondary packaging to group the bottles for 
each subject will also be used.  Only 1 bottle at a time is 
to be dispensed to a subject.  If necessary (eg, lost or 
damaged bottle), a second 
bottle  will be available to 
dispense.  
Table 8  Updated definition of Concurrent medication and 
concurrent procedure to include during the study  Clarified to include post-enrollment addition s 
12.5.4. Amendment  4 Summary  
Study  Title :  A Phase 1/2a Assessment  of WB007  Ophthalmic  Solution in  Subjects  with  
Primary  Open -Angle Glaucoma or Ocular  Hypertension 
Protocol  WB007-001_04 (Amendment 4);   Date  of Amendment :  September  2020 
Section(s)  Revision Rationale 
4.1 Exclusion 15: removed “evidence of unilateral cataract 
surgery ” from the criterion .  The criterion now is: 
“Evidence of cataract surgery resulting in complications 
(eg, capsular rupture) in the study eye.”  Loosened the criterion to 
ensure efficient enrollment of the study population without jeopardizing the outcome of the study.   
4.1 and 8.4 .1 Modified exclusion 27: “ Previous participation in this 
study” to “Previous  randomization  in Part 2 of this 
study”. 
 
Part 1 Day 2 (Hour 0): removed statement not allowing 
participation in Part 2  for subjects who participated in 
Part 1 . Allow for subjects who 
participated in Part 1of the 
study to participate in Part 2.  A 
subject who participates in both 
Parts 1 and 2 will be counted only once in the total number of participants of the study.  
 
Whitecap  Biosciences  Confidential   Protocol  WB007 -001_05  
 79 2021.01.30  12.5.5. Amendment  5 Summary  
Study  Title :  A Phase 1/2a Assessment  of WB007  Ophthalmic  Solution in  Subjects  with  
Primary  Open -Angle Glaucoma or Ocular  Hypertension 
Protocol  WB007-001_05 (Amendment 5);   Date  of Amendment :  January  2021 
Section(s)  Revision  Rationale  
Synopsis, 3.2.1, 
7.5, 8.3.2, Table 
8, 12.4.  Further clarified wording on the role of the IWRS for 
selection of study eye.  IWRS was used to confirm IOP 
eligibility.  Designation of the 
study eye was based on the  
algorithm  pre-specified in the 
protocol in Section 9.3.1. 1. 
Synopsis, 3, 
9.3.1.1, 
 Clarified the wording for the primary efficacy analysis.  
The primary efficacy analysis is the within -group mean 
change from baseline at Hour 2, the time of peak efficacy 
of timolol.  The protocol wording was 
clarified to align with  the 
Statistical Analysis Plan (SAP) .     
Synopsis, 9.2 
 
 Clarified the sample size power calculation to include the 
power to detect within -group mean change from baseline 
of at least a 3 mm Hg for the primary endpoint assuming 
a standard deviation of 2.5 with two- sided alpha = 0.05.”  
 
In Section 9.2, deleted th e last paragraph and replaced the 
3rd sentence under the table to align with the protocol 
synopsis.  The protocol wording was 
clarified to align with  the SAP.    
 